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ABSTRACT 
 
The adverse effects of maternal smoking on infant mortality and morbidity has been 
well documented in the literature. Maternal tobacco use is causally associated with fetal 
growth restriction and correlates negatively with folate intake and metabolism. Studies have 
examined the association between smoking and folate levels during pregnancy, but very few 
have assessed this relationship using objective and accurate measures of both variables. 
Furthermore, despite evidence of a causal association between smoking in pregnancy and 
intrauterine growth restriction, and a plausible relationship between tobacco use and low 
maternal folate which is required for optimal fetal growth, no experimental study has 
investigated the potential benefit of folic acid in mitigating the adverse effects of maternal 
smoking on fetal outcomes.  
The objectives of this study were to investigate the relationship between maternal 
smoking and folate levels and examine the efficacy of higher-strength folic acid 
supplementation, in combination with enrollment in a smoking cessation program, in 
promoting fetal body and brain growth. Our hypothesis was that women who smoke during 
pregnancy have lower peri-conceptional folic acid reserves than non-smoker pregnant women 
and that folic acid reserves will decrease with increasing cotinine level.  Additionally, smoker 
pregnant women on higher-strength folic acid (4mg daily) in combination with smoking 
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cessation programs will experience faster fetal brain growth and have infants with larger body 
size at birth compared to smokers on the standard dose of folic acid (0.8mg daily).  
Participants were pregnant women (smokers and non-smokers) who received antenatal 
care between 2010-2014 at the Genesis Clinic of Tampa, a community health center affiliated 
with the Department of Obstetrics and Gynecology of the University of South Florida (USF). 
They were aged 18-44 years and had a gestational age of less than 21 weeks at study 
enrollment. To determine the peri-conceptional folic acid reserves in smoking versus non-
smoking women during pregnancy and associated sociodemographic factors, baseline (cross-
sectional) data from a double-blinded randomized controlled trial were analyzed using Tobit 
regression models (n=496). Smoking information was assessed using salivary cotinine, a 
sensitive and specific tobacco use biomarker. Folate reserve was measured using red blood cell 
folate. To investigate the efficacy of higher-strength folic acid on fetal body and brain size, 
baseline and follow-up data from pregnant smokers enrolled in the randomized controlled trial 
were utilized (n=345). All primary analyses of the clinical trial data were conducted on a 
modified intention-to-treat basis and included participants who completed the trial with an 
observed endpoint, irrespective of compliance to protocol. Multilevel modeling, linear 
regression, and log-binomial regression analyses were conducted. 
A significant inverse association between salivary cotinine level and periconceptional 
red blood cell folate concentration was found among pregnant women in the early to mid-
pregnancy period. Smokers on high-dose folate during pregnancy had infants with a 140.38g 
higher birth weight than infants of their counterparts on standard dose folate (P =0.047). 
Mothers who received higher strength folate had a 31.0% lower risk of having babies with SGA 
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compared to their mothers on the standard-dose (adjusted relative risk-ARR=0.69, 95% CI: 
0.46–1.03; (P =0.073)). High-dose folate had no significant effect on the intrauterine rate of 
growth in head circumference, and head circumference and brain weight at birth in our trial 
sample. However, the brain-body ratio of infants of mothers who received high-dose treatment 
was 0.33 percentage-point lower than that for infants of mothers who received the standard 
dose of folate (P =0.044). 
Higher strength folic acid supplementation in pregnant women who smoke might be a 
cost-effective and safe option to improve birth outcomes and reduce low birth weight and SGA 
associated infant morbidity and mortality. Future studies with larger sample sizes and diverse 
populations are indicated to confirm or refute the results of this study. Randomized controlled 
trials starting during the preconception period and with follow-up until delivery are warranted, 
to identify the most folate-sensitive period of fetal growth and determine the optimal dose of 
folic acid supplement. Further research investigating several pathways through which the 
effects of prenatal smoking on adverse birth outcomes can be mitigated is needed. 
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CHAPTER ONE: 
 
INTRODUCTION 
 
The adverse effects of maternal tobacco smoking on fetal development have been well 
documented. Smoking during pregnancy is associated with increased risks for a reduction in 
fetal body and brain size,1-4 indices that are associated with future adverse health outcomes 
and increased mortality. There is overwhelming evidence of a causal association between 
smoking in pregnancy and intrauterine growth restriction,1-3,5 and a plausible relationship 
between smoking and low maternal folate6-8 which is required for optimal fetal growth. Despite 
these well-established relationships, no experimental study has investigated the benefit of folic 
acid supplementation in reducing the adverse effects of maternal smoking on fetal outcomes. 
 
STUDY RATIONALE  
Despite the known risk of higher mortality and morbidity rates among infants born to 
smoking mothers, approximately 12% of women continue to smoke during pregnancy.3 
Maternal smoking is causally associated with fetal growth restriction.1-4 Smoking also has a 
negative impact on folate metabolism, and diet quality including folate intake.9-10 Adequate 
folate intake, particularly in pregnancy is required for cell division, and deficiency of this 
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essential micronutrient has been associated with adverse birth outcomes such as preterm birth 
and congenital abnormalities.8,11,12 
Several studies have examined the association between smoking and folate level in 
pregnancy13-16 but very few have assessed this association using objective and specific measures 
of both smoking and folate.17 Most of the previous studies utilized self-reports to distinguish 
smokers and nonsmokers.13-15 Recently, Prasodjo and colleagues17   examined the relationship 
between tobacco smoke exposure and whole blood folate concentrations in pregnant women 
from Cincinnati, Ohio. The investigators could not calculate RBC folate, which would have 
allowed for direct comparability with folate status of women from prior studies. In addition, 
folate was measured using samples that had been stored for 4-6 years so folate may have 
degraded due to storage length. To demonstrate a valid association between the smoking in 
pregnancy and folate, it is important that both the exposure and outcome variables are directly 
and accurately measured. This current study attempted to fill this gap in the literature. With the 
use of baseline data from a randomized controlled trial, we assessed the periconceptional folic 
acid reserves in smoking and non-smoking women, and factors associated with 
periconceptional folate levels during pregnancy. Smoking information was based on a sensitive 
and specific tobacco smoke biomarker. Furthermore, folate level was measured using red blood 
cell folate (also called erythrocyte folate), which is a better indicator of long-term folate storage 
than serum folate.18-19 
The association between maternal smoking during pregnancy and fetal body size has 
been investigated in several cross-sectional and longitudinal studies.4,20,21 These studies found 
that continued smoking during pregnancy leads to intrauterine growth restriction and reduced 
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growth of fetal head circumference and biparietal diameter which are parameters of total 
growth restriction in fetuses.4,20-22 In the Generation R European study, Bakker and colleagues23 
found that folic acid supplements might reduce some of the adverse effects of maternal 
smoking on fetal growth and neonatal outcomes. These investigators conducted an 
observational, prospective and population-based cohort study collecting information on 
smoking and folic acid supplement use during pregnancy by use of questionnaires.23 Limitations 
of this self-reported measure of exposures include underreporting of smoking status because 
low correlations exist between cotinine concentrations and self-reported smoking status,24 over 
reporting of use of folic acid supplements and subsequent misclassification of these variables. 
The researchers concluded that the results from their observational study should be considered 
hypothesis-generating and be confirmed using randomized controlled trials. 23 This current 
study built on the findings in the Bakker et al23 study.  
With the use of primary data from a double-blinded randomized controlled trial, and 
validated biomarkers of folate and tobacco exposure, we tested the hypothesis of reduced 
adverse effects of maternal smoking on fetal growth by specifically examining the effects of 
higher strength folic acid supplementation on fetal brain and body size. To the best of our 
knowledge, this randomized clinical trial is the first to investigate the efficacy of folic acid in 
combination with smoking cessation programs in preventing adverse birth outcomes in smoking 
mothers during pregnancy.  
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SPECIFIC AIMS 
The goal of this research was to understand the relationships between folate and fetal 
development among smoking mothers and identify factors that may promote fetal growth and 
development among mothers who smoke during pregnancy. The objective of the study was to 
determine the factors associated with periconceptional folic acid reserve and investigate the 
efficacy of folic acid in combination with smoking cessation in enhancing fetal brain growth and 
body size among smoking mothers. The specific aims of this research were:  
1. To examine the periconceptional folic acid reserves among smoking vs. non-smoking 
women during pregnancy and associated sociodemographic factors. 
2. To determine whether higher-strength folic acid in combination with enrollment in 
smoking cessation programs will prevent a reduction in fetal body size among smokers 
in pregnancy. 
3. To determine the effect of higher-strength folic acid in combination with enrollment in 
smoking cessation programs on fetal brain growth and development among women 
who smoked during pregnancy.  
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CHAPTER TWO: 
 
MANUSCRIPT 1: MATERNAL COTININE LEVELS AND RED BLOOD CELL BLOOD FOLATE 
CONCENTRATIONS IN THE PERICONCEPTIONAL PERIOD 
 
ABSTRACT 
Studies have examined the association between tobacco use and folate levels in 
pregnancy, yet very few have assessed this relationship using objective and accurate measures 
of both smoking and folate. In this study, the periconceptional folic acid reserves in smoking 
and non-smoking women were evaluated, along with factors associated with periconceptional 
folate levels during pregnancy. Smoking information, based on salivary cotinine, a highly 
sensitive and specific tobacco smoke exposure biomarker was utilized. Furthermore, folate was 
assessed using red blood cell (RBC) folate, which is a superior indicator of long-term folate 
storage compared to serum folate. Participants were pregnant women who received antenatal 
care between 2010-2015 at the Genesis Clinic of Tampa, a community health center affiliated 
with the Department of Obstetrics and Gynecology of the University of South Florida (USF). A 
total of 496 women were enrolled in the study.  
  Associations between smoking status/maternal salivary cotinine concentrations, 
sociodemographic factors and folate concentrations were investigated using Tobit regression 
analyses. Non-smokers had nearly 20 ng/mL higher mean concentration of RBC folate than 
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smokers, but the difference was not statistically significant (p-value= 0.4213). In contrast, 
salivary cotinine levels were significantly associated with decreased erythrocyte blood folate 
concentrations. For every one level increase in cotinine, folate levels reduced by 11.43 ng/mL 
(p-value=0.032). Maternal body mass index, gestational age, stress, and depression were also 
associated with folate levels. 
Given the role of folic acid in fetal development, the identification of a modifiable risk factor 
associated with low folate concentrations, such as smoking, may offer opportunities to prevent 
adverse fetal outcomes. Thus, higher strength folic acid supplementation in smokers, 
particularly in those who smoke frequently, might be beneficial in improving maternal RBC 
folate concentrations and preventing adverse birth outcomes linked with tobacco exposure.  
 
INTRODUCTION 
Adequate folate intake during pregnancy is required for proper cell division, fetal 
growth and development.25-26 Folate deficiency has been associated with health problems in 
both mothers (such as anemia, peripheral neuropathy) and infants (such as preterm birth and 
congenital abnormalities).26,27 The negative association between smoking in pregnancy and folic 
acid intake and metabolism is well documented.6,13,17,28-30 Tobacco smoke exposure during 
pregnancy may increase disease risk among children by reducing folate bioavailability during 
the critical period of fetal development.13,14,16, 31,32 Despite substantial evidence of the 
deleterious health effects of smoking, periconceptional smoking is prevalent. About 25.4% of 
women in the United States smoke in the three months preceding pregnancy, and 
approximately 15.0% of women smoke during the last trimester of gestation.33,34 Additionally, 
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about one-third of women of reproductive age who are at risk of becoming pregnant are also 
exposed to environmental tobacco smoke i.e. second-hand exposure.35 Public health initiatives 
have helped reduce the prevalence of smoking in pregnancy over the past few decades but 
smoking remains relatively common among subgroups of these population such as women of 
lower socioeconomic status.5  
Studies have examined the association between tobacco use and folate level in 
pregnancy,13-16 yet very few have assessed this relationship using objective and accurate 
measures of both smoking and folate.17 Most previous studies utilized self-reports to 
distinguish smokers and nonsmokers, while also including women with second-hand smoking 
exposure as nonsmokers.13-15 Only two previous studies employed validated biomarkers of both 
folate and smoking. 16-17 Pagan K et al16 measured smoking using serum thiocyanate, which is 
not a specific biomarker. Numerous factors other than tobacco smoke exposure affect serum 
thiocyanate, and these include exposure to cyanides and thiocyanate producing foods, such as 
cabbage, garlic, and almonds.36 Prasodjo et al17 assessed folate using whole blood folate that 
had been stored for approximately 6 years. Folate degradation was likely in their sample. To 
demonstrate a valid association between smoking in pregnancy and folate level, it is important 
that both the exposure and outcome variables are directly and accurately measured. This study 
proposes to fill the literature gap in this regard, and would lead to better understanding of 
prenatal factors that may contribute to adverse birth outcomes.   
The periconceptional folic acid reserves in smoking and non-smoking women were 
assessed, along with factors associated with periconceptional folate levels during pregnancy. 
Smoking information, based on a highly sensitive and specific tobacco smoke biomarker, was 
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utilized. Furthermore, folate was assessed using red blood cell folate (erythrocyte folate), which 
is a superior indicator of long-term folate storage compared to serum folate.18, 19 
 
METHODS 
 
Participants 
This study used baseline data collected from smoking pregnant women who were enrolled in a 
randomized clinical trial on the efficacy of high-dose folate in improving birth outcomes. We 
also collected cross-sectional data from non-smoking pregnant women recruited to compare 
their periconceptional folate reserve with the smokers’. Participants were pregnant women 
who received antenatal care between 2010-2015 at the Genesis Clinic of Tampa, a community 
health center affiliated with the Department of Obstetrics and Gynecology of the University of 
South Florida (USF).  Women who receive health care from this center are usually of low 
socioeconomic status and mostly uninsured or are covered by Medicaid or emergency Medicaid 
for pregnancy. 
 Flyers advertising the research study were posted around the clinic and distributed with 
new patient intake forms. The intake clerk or study staff assessed each woman’s level of 
interest. Written permission was obtained from interested women who were less than 21 
weeks pregnant, based on a calculation from the first day of their last menstrual period (LMP). 
Study personnel screened for eligibility which was defined as age 18-44 years, less than 21 
weeks gestation at enrollment as confirmed by LMP and residency in Tampa, Florida, or 
surrounding areas.  Participants were excluded if there was evidence of an indication for 
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chronic blood transfusion and treatment with anti-convulsant medication. Women receiving 
chronic blood transfusion may have inaccurate measures of folate RBC levels due to transfused 
red blood cells (RBC).  Patients treated with anticonvulsants can have folic acid deficiency as a 
side effect of the medication.37 Written informed consent, which was available in both English 
and Spanish was obtained from all the participating women.  A total of 496 women were 
enrolled in the study.  
Following informed consent and before data collection, all participants had vaginal 
ultrasonography to confirm the viability of the fetus and establish gestational age.  Study 
questionnaires and laboratory assessments of salivary cotinine and erythrocyte folate were 
then completed. The study was funded by the James and Esther King Biomedical Research 
Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987), and was 
registered at ClinicalTrials.gov (Identifier: NCT01248260). The trial protocol was approved by 
the Institutional Review Board of the University of South Florida. 
 
Outcome Assessment 
Periconceptional folic acid reserve was measured by assessing maternal erythrocyte 
folate concentration at study baseline (less than 21 weeks GA) using enzyme-linked 
immunosorbent assay (ELISA). RBC folate was the preferred folate biomarker because it has 
good correlation with serum folate and has advantages of long-term stability and reduced 
susceptibility to sudden changes in diet (Galloway, 2013). Laboratory analysis was conducted at 
Quest Diagnostics using EDTA blood. At this laboratory, the standard reference range for RBC 
folate is 280 ng/mL to 1000 ng/ml. Folate levels greater than 1000 ng/ml were reported as 
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>1000ng/ml. However, for the purpose of data analysis, we truncated the >1000ng/ml values 
(n=58) to 1000 ng/mL, 38 and defined folate level as a continuous variable.  
 
Exposure Assessment 
Periconceptional maternal smoking was measured through the use of a rapid semi-
quantitative screening test called NicAlert (Jant Pharmacal Corporation, Encino, CA). Maternal 
saliva was tested for the presence of cotinine, a biological marker for nicotine. Salivary cotinine 
analysis is the most sensitive and specific of the three types of cotinine measures.39 This 
method has a sensitivity of 99% and specificity of 82%.39 The cotinine test strip displays seven 
levels (0-6), each of which represents a range of salivary cotinine concentrations. Higher levels 
on the strip indicate higher range of cotinine.  Based on the manufacturer’s guidelines, 
individuals with reading at level 0 (cotinine concentration <10 ng/mL) are considered nonusers 
of tobacco products while participants with at least a level 1 result are considered smokers. 
Individuals with a cotinine level of 1 are either light active smokers or passive smokers. 
Participants in this study were classified as smokers (active and passive) and non-smokers 
based on this guideline. Maternal smoking was also treated as a continuous explanatory 
variable in our analysis (cotinine level).  
 
Potential Confounders 
Based on prior knowledge, a number of maternal characteristics were considered as 
potential confounding factors due to their demonstrated association with folate levels and 
smoking. 6,17,33,40,41 These include sociodemographic factors (such as maternal age, race, marital 
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status, and insurance status), and perinatal factors such maternal body mass index (BMI)), 
depression, stress, and gestational age. Smoking is strongly associated with psychological 
factors such as depression and stress.42,43  
Race/ethnicity was categorized into three groups: non-Hispanic black (black), non-
Hispanic white (white), and other (includes Hispanic). Age was defined as both continuous and 
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized 
as either married or unmarried, the latter included divorced, separated and unknown marital 
status.  Insurance (health insurance) was categorized as private or public/uninsured. BMI was 
calculated using maternal self-reported pre-pregnancy weight and height measured at 
enrollment. BMI was calculated as weight (kg)/ height (m)2 and categorized into normal 
(<25·0kg/m2), overweight (25·0–29·9kg/m2) and obese (≥30·0kg/m2). Although 5 women had 
BMI below 18.5 (underweight), they were included in the normal BMI group due to limited 
sample.  Gestational age was based on ultrasound fetal dating at study enrollment. Depression 
was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is a validated tool for 
assessing ante-natal and post-natal depressive symptoms.44 Mothers who score above 12 or 13 
on the scale are likely to be suffering from depression.45 We dichotomized this variable as high 
and low, using a cut-off point of 12. Stress was measured using the Perceived Stress Scale (PSS-
14) scale, which is a validated tool for comparisons between people in study samples.46 As a 
result, women who had a score equal to or greater than the mean stress score for the sample 
were classified as having high-stress levels, while those who had a score below the mean were 
classified as having low-stress levels. 
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Statistical Analyses 
 The projected sample size required to evaluate differences in periconceptional folic acid 
reserves in women during pregnancy was 106 (53 smokers and non-smokers respectively).  This 
estimation was based on the following assumptions: (1) type 1 error rate of 5%; (2) 80% power 
(3) minimal odds ratio of 1.2 for folate values reported among non-smoking vs. smoking 
pregnant women; and (4) a standard deviation of 7.6 and 8.9 for smoking and non-smoking 
mothers respectively.10,11,15,47 In this study, data was available on 496 women, suggesting 
adequate power to detect a difference in periconceptional folic acid reserves among smoking 
vs. non-smoking women if it exists. 
Frequencies and percentages were used to describe the categorical maternal 
sociodemographic and health-related characteristics of the study population by smoking status. 
Chi-square tests of independence were used to test for differences in proportions. Means and 
standard deviations were calculated for selected continuous variables. Spearman correlation 
coefficient was used to assess the relationships between the continuous covariates, cotinine 
level and erythrocyte folate. The outcome of interest, folate level was plotted using histogram, 
and the distribution was assessed for normality. The plot suggests non-normal distribution 
which could be explained by the laboratory’s folate reporting practices described earlier. As 
shown in the Figure 2.1, if folate levels were not right-censored, the distribution of folate 
concentration could have been approximately normal. 
Due to the observed distribution of folate, parametric and nonparametric bivariate 
analyses were conducted. Mean/standard deviation and median/interquartile range (IQR) 
blood folate concentrations were calculated by socio-demographic and lifestyle characteristics. 
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Analysis of variance was used to examine if there were significant differences in the mean folic 
acid reserves by selected characteristics of participants. The differences in the median folic acid 
reserves by study participants’ characteristics were tested using Kruskal-Wallis test. It is a 
nonparametric hypothesis test for comparing two or more independent samples, and is very 
sensitive to differences in both location and shape of the empirical distribution functions of the 
samples.48  
Additionally, the associations between the study exposures (smoking status & maternal 
salivary cotinine concentrations), sociodemographic and lifestyle factors and folate 
concentrations were investigated using Tobit regression. This modeling method, which is also 
known as censored regression, is the appropriate method for estimating linear relationships 
between variables when the dependent variable is right-censored.49,50 The relationship 
between the exposure variables and folate were examined in separate models. In the 
regression models, we controlled for variables identified as potential confounders from prior 
studies or from our analyses (variables associated with either cotinine or folate levels). 
Stepwise regression modeling was utilized and model fit was examined based on AIC. Using the 
variables in the adjusted model, we assessed for multicollinearity and found that depression 
score and stress score were fairly strongly correlated (r=0.66). Thus, an interaction term was 
introduced between these variables. Adjusted mean differences in folate levels were estimated 
and reported from the models with the best fit. All hypothesis tests were two-tailed with a type 
1 error rate fixed at 5%.  SAS version 9.4 (SAS Institute, Cary, NC) was used to perform all 
statistical analyses.  
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RESULTS 
A total of 496 pregnant women participated in the study; 345 smokers (69.6%) and 151 
non-smokers (30.4%). The mean age and gestational age of the participants at enrollment were 
27.0 years (SD±5.76) and 12.15 weeks (SD±3.85) respectively. Table 2.1 shows the baseline 
characteristics of the study sample by maternal smoking status. Majority were aged 25-34 years 
(49.5%), unmarried (82.5%), had public/no insurance (93.2%), obese (42.0%), and enrolled in 
the study during the first trimester of pregnancy (57.9%). Significant differences in smoking 
status were observed by race, marital status, insurance status, depression score and maternal 
perceived stress score (p-values < 0.005). Pregnant women who smoked during pregnancy were 
more likely to be Non-Hispanic white, unmarried, and having public/ no insurance. They were 
also more likely to have high depression scores and high perceived stress.  
In Tables 2.1 and A2.1 in Appendices, we present the baseline characteristics of the 
study sample by the mean and median blood folate levels respectively.  The results from 
parametric and non-parametric tests were similar. Thus, we reported only the findings from the 
parametric tests. The mean folate level was 718.3 ± 183.2 ng/mL, and there was no difference 
in folate levels by smoking status. However, statistically significant differences were observed in 
the folate level by BMI and trimester of gestation at baseline. Obese women had significantly 
higher mean blood folate (741.9 ng/mL) than overweight (714.7 ng/mL) and those with normal 
BMI (688.5 ng/mL). Red blood cell folate concentrations were highest among women aged 35 
years and older (though not significantly different than levels for other age groups) and women 
whose folate level was measured during their second trimester of pregnancy. In the correlation 
matrices, folate was found to correlate positively with gestational age at study enrollment (p-
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value< 0.001) (Table A2.2. in Appendices), while cotinine correlated positively with depression 
and stress scores (Table A2.3. in Appendices). 
Table 2.3 shows the adjusted estimates of the association between smoking status 
(examined as a binary variable) and folate concentrations from Tobit regression. Non-smokers 
had nearly 20 ng/mL higher mean level of folate than smokers, but the difference was not 
statistically significant (p-value= 0.4213). In contrast, the association between smoking 
examined as a continuous variable and folate levels were statistically significant. Salivary 
cotinine levels were significantly associated with decreased erythrocyte blood folate 
concentrations (Table 2.4). For every one level increase in cotinine, folate levels reduced by 
11.43 ng/mL (p-value=0.032). Gestational age was also found to be associated with folate 
concentration. The mean folate levels increased by about 15.5 ng/mL per week in the 
periconceptional period (p-value<0.001).  Compared to obese women, adjusted blood folate 
concentrations were 64 ng/mL (p-value=0.003) lower among women with normal BMI. A 
significant negative interaction effect of stress and depression was observed with folate levels 
(p-value=0.0083). This indicates that the higher stress scores become, the more negative is the 
effect of depression on folate levels.  No significant associations were found between maternal 
age, marital status, race, insurance and erythrocyte blood folate concentrations. 
 
DISCUSSION 
An inverse association between salivary cotinine level and periconceptional red blood 
cell folate concentration was found among pregnant women in the early to mid-pregnancy 
period. Interestingly, there were no significant differences in the mean folate levels by smoking 
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status. We also found a positive gestational age effect. Furthermore, substantial reductions in 
folate were also observed among normal weight mothers compared to obese mothers. 
Several prior studies have found negative associations between smoking and folate 
concentrations among pregnant women13-16; however, few studies have used specific 
biomarkers of both tobacco exposure and folate.17 Consistent with our findings, Prasodjo et al17 
observed an inverse relationship between tobacco exposure and RBC folate levels in pregnant 
women using whole blood biomarkers of folate and smoking but their finding was not 
statistically significant. The researchers attributed this result to insufficient statistical power. 
The magnitude of the reduction in folate levels they found among women exposed to second-
hand smoking (SHS) was lower than that in active smokers-similar to our findings of increasing 
cotinine levels associated with lower folate concentrations. However, the authors did not 
determine RBC folate, which would have allowed direct comparison with folate status of 
women from our study.  
We observed no significant differences in mean folate levels by smoking status, and this 
result is consistent with previous studies, which reported lower but non-significantly different 
folate levels between smokers and non-smokers.16,51 In contrast, earlier studies found smokers 
to have significantly lower folate concentrations. 6,8,17 The absence of a significant association 
for smoking status, with folate, could be explained by an adequate dietary and supplemental 
intake of folate among the participants. Unfortunately, we could not control for confounding 
from diet and many other variables in this study.  The lack of significant difference found in the 
binary form of tobacco exposure variable (smoker vs. non-smoker) might also be attributed to 
the well-known statistical problems associated with categorization of continuous variables. 
17 
 
Categorization can result in loss of information or statistical power and hide true 
relationships.52,53 
A positive correlation was observed between gestational age and folate concentrations. 
Furthermore, substantial reductions in folate were found among normal weight mothers 
compared to obese mothers. Consistent with these findings, a recent cross-sectional study 
among pregnant women with similar mean gestational age at enrollment as the sample in this 
study (less than 20 weeks), found gestational age to be positively associated with RBC folate. 
BMI was also positively related to RBC folate in both of their adjusted and unadjusted analyses. 
54 It is important to note that the same study observed a negative (contrasting) association 
between gestational age and BMI on serum folate. In previous studies among non-pregnant 
women, 55-57 having normal weight was found to be associated with lower concentrations of 
RBC folate but higher levels of plasma folate compared to being obese. This was observed 
despite evidence of lower folate intake among obese women.55 As a result, our findings must 
be interpreted in the context of the folate biomarker used.  RBC folate may not reflect freely 
available folate at the cellular level in pregnant women because absorption and breakdown of 
folate are altered by maternal adiposity.54 
Because this study was cross-sectional, our ability to infer causality in the association 
between increasing cotinine level and lower RBC folate concentration was limited. Although 
several sociodemographic, lifestyle and health-related potential confounders were taken into 
account, it was not possible to control for dietary intake of folate, fruits, vegetables, and 
alcohol. Folate intake and plasma vitamin C concentrations are known predictors of folate 
levels. 58 The direction of the effect of this residual confounding is unclear, however, this may 
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be minimal because the participants are of similar income level and may have similar dietary 
habits. Another limitation of this study is our inability to generalize the findings to other low-
income populations.  Participants were not randomly selected and those who chose to be 
included in the study could be different from those who declined. In this instance, the 
respondents might be more health conscious and, therefore, findings could be biased towards 
the null.  
One major strength of the study is the use of validated biomarkers of both the exposure 
and outcome. Salivary cotinine analysis is the most sensitive and specific of the three types of 
cotinine measures. 39 Most previous studies used self-reported data on smoking or less 
accurate measures of cotinine such as serum cotinine. In our study however, folate 
concentrations were measured using red blood cell folate, which is a better indicator of long-
term folate storage than serum folate.18,19 By measuring RBC folate at less than 21 weeks GA, 
we were able to reflect more accurately the periconceptional folate levels among these 
women.  
Given the role of folic acid in fetal development,25,26 the identification of a modifiable 
risk factor associated with low folate concentrations, such as smoking, may offer opportunities 
to prevent adverse fetal outcomes and reduce consequent disease risk in adulthood. 27,47,59 
Smoking cessation during preconception or periconceptional periods could improve birth 
outcomes,60 yet smoking cessation programs during pregnancy are associated with high failure 
rates, especially in low-income subpopulations.61,62 This study suggests that smokers may have 
a lower RBC folate than non-smokers, and that a significant negative correlation does exist 
between cotinine levels and folate concentrations. Thus, higher strength folic acid 
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supplementation in smokers, particularly in those who smoke frequently, might be an avenue 
to increase folate concentrations and improve adverse developmental and birth outcomes 
linked with tobacco exposure.  
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Table 2.1. Baseline characteristics of participants by maternal smoking status (n = 496) 
 
 
 
Variables 
 
 
Total   
n (%) 
 
 
Smokers  
n (%) 
 
 
Non-Smokers 
n (%) 
 
 
 
P-value 
Overall 496 (100.0) 345 (69.6) 151 (30.4)  
Gestational age, mean (SD)  12.3 (3.9) 11.7 (3.7) 0.1339 
Maternal Age    0.6538 
     18–24 194 (39.1) 134 (38.8) 60 (39.7)  
     25–34 245 (49.4) 174 (50.4) 71 (47.0)  
     ≥35   57 (11.5)   37 (10.7) 20 (13.2)  
Maternal Race    <.0001 
    Non-Hispanic white 187 (37.7) 148 (42.9) 39 (25.8)  
    Non-Hispanic black 186 (37.5) 140 (40.6) 46 (30.5)  
    Other 123 (24.8)  57 (16.5) 66 (43.7)  
Marital Status    <.0001 
     Married   87 (17.5)   34 (9.9) 53 (35.1)  
     Unmarried 409 (82.5) 311 (90.1) 98 (64.9)  
Insurance Type    0.0003 
    Private   34 (6.8) 17 (4.9) 17 (11.3)  
    Public/ Uninsured 462 (93.2) 328 (95.1) 134 (88.8)  
Trimester     0.6037 
     First  287 (57.9) 197 (57.1) 90 (59.6)  
     Second  209 (42.1) 148 (42.9) 61 (40.4)  
Body Mass Index∗    0.5198 
     <25 156 (31.8) 111 (32.4) 45 (30.4)  
     25–30 129 (26.3)   85 (24.8) 44 (29.7)  
     >30 206 (42.0) 147 (42.9) 59 (39.9)  
Maternal Depression Score    0.0005 
     <12 409 (82.5) 271 (78.5) 138 (91.4)  
     ≥12   87 (17.5) 74 (21.5)    13 (8.6)  
Perceived Stress Score    <0.0001 
    Low 259 (52.2) 154 (44.6) 105 (69.5)  
    High 237 (47.8) 191 (55.4)   46 (30.5)  
Trimester=Trimester at study enrollment and data collection 
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Table 2.2. Baseline characteristics of the study sample by mean blood folate concentrations 
(n = 496) 
Variables Erythrocyte Folate, ng/mL  
 Mean (SD) P-value 
Overall 718.3 (183.2)  
Maternal Age  0.4091 
     18–24 710.5 (176.1)  
     25–34 717.7 (184.3)  
     ≥35 747.4 (200.5)  
Maternal Race  0.6240 
    Non-Hispanic white 727.6 (188.1)  
    Non-Hispanic black 709.1 (185.9)  
    Other 718.1 (172.2)  
Marital Status  0.9691 
     Married 717.6 (184.9)  
     Unmarried 718.4 (183.1)  
Insurance Type  0.6517 
    Private 704.6 (152.2)  
     Public /Uninsured 719. 3 (185.4)  
Trimester   <0.001 
     First  668.3 (181.2)  
     Second  786.7 (163.2)  
Body Mass Index  0.0220 
     <25 688.5 (177.3)  
     25–30 714.7 (184.9)  
     >30 741.9 (183.4)  
Depression Score  0.5452 
     <12 718.0 (180.0)  
     ≥12 719.6 (202.5)  
Perceived Stress Score  0.3081 
    Low 710.2 (186.7)  
    High 727.0 (179.4)  
Smoke Tobacco  0.9700 
     Yes 718.5 (186.9)  
     No 717.8 (175.1)  
Trimester=Trimester at study enrollment and data collection 
 
 
 
 
22 
 
 
Table 2.3. Adjusted associations between smoking status and maternal periconceptional red 
blood folate concentrations (n=496) 
Variables β  SE p-value 
Smoke Tobacco    
     Yes 17.27 21.17 0.4213 
     No ref - - 
Gestational Age  15.26 2.32 <0.001 
Maternal Depression Score 12.50 4.92 0.011 
Perceived Stress Score 2.48 1.76 0.1575 
Race    
    Non-Hispanic white ref - - 
    Non-Hispanic black -16.93 20.71 0.4137 
    Other -13.30 23.90 0.5779 
Body Mass Index∗    
     >30 ref - - 
     <25 -64.91 20.90 0.002 
     25–30 -29.07 22.14 0.1892 
Depression Score*Stress Score -0.42 0.16 0.010 
Adjusted by Tobit regression for gestational age at study enrollment or data collection, perceived stress, 
depression, race, & BMI at enrollment. β= Estimate; SE= Standard error; ref= Reference group. 
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Table 2.4. Adjusted associations between cotinine levels and maternal periconceptional red 
blood folate concentrations (n=496) 
Variables β  SE p-value 
Baseline cotinine -11.43 5.45 0.0320 
Gestational age  15.53 5.33 <0.001 
Maternal Depression Score 13.13 4.90 0.007 
Perceived Stress Score 2.81 1.75 0.109 
Race    
    Non-Hispanic white ref - - 
    Non-Hispanic black -25.00 21.10 0.235 
    Other -23.10 24.07 0.337 
Body mass index∗    
     >30 ref - - 
     <25 -64.34 20.88 0.002 
     25–30 -28.84 22.10 0.191 
Depression Score*Stress Score -0.42 0.16 0.007 
*Adjusted by Tobit regression for gestational age at study enrollment or data collection, perceived stress, 
depression, race, & BMI at enrollment. β= Estimate; SE= Standard error; ref= Reference group. 
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Figure 2.1. Distribution of periconceptional erythrocyte folate concentrations (ng/ml) 
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CHAPTER THREE: 
 
 
MANUSCRIPT 2: EFFICACY OF HIGHER-STRENGTH FOLIC ACID ON FETAL BODY SIZE AMONG 
WOMEN WHO SMOKED DURING PREGNANCY 
 
ABSTRACT 
Despite evidence of a causal association between smoking in pregnancy and 
intrauterine growth restriction, a plausible relationship between tobacco use and low maternal 
folate and a possibility of folic acid supplement improving birth outcomes among smokers, no 
experimental study has investigated the benefit of folic acid in reducing the adverse effects of 
maternal smoking on fetal outcomes. In this study, we examined the efficacy of higher-strength 
folic acid supplementation in combination with smoking cessation programs in preventing a 
reduction in fetal body size among smoking pregnant women. Primary data from a double-
blinded randomized controlled trial which utilized validated tools and biomarkers were 
analyzed. Participants were pregnant women who received antenatal care at the Genesis Clinic 
of Tampa between 2010-2015.  A total of 345 pregnant smokers were enrolled in the study at a 
gestational age of less than 21 weeks and were followed until delivery. 
All primary analyses were conducted on a modified intention-to-treat basis and included 
participants who completed the trial with an observed endpoint, irrespective of compliance to 
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protocol. The relative risks of having an SGA neonate among mothers who had the high dose 
treatment vs. standard dose of folic acid was estimated using a log-binomial regression model. 
Mean differences in infant birthweight between treatment groups was assessed using multiple 
linear regression analysis. 
The baseline characteristics of the participants in the two treatment groups were well 
matched with the exception of race. The incidence of SGA was 21.4% (n=74), and the mean 
(±SD) infant weight at birth was 3059.0g (±640.2). Smokers on high-dose folate during 
pregnancy had infants with a 140.38g higher birth weight than their counterparts on standard 
dose folate (P =0.047). Mothers who received higher strength folate had a 31.0% lower risk of 
having babies with SGA compared to their counterparts on the standard-dose (adjusted relative 
risk-ARR=0.69, 95% CI: 0.46–1.03; (P =0.073)). 
In conclusion, higher strength folic acid supplementation in pregnant women who 
smoke might be a safe and cost-effective way to improve birth outcomes and reduce low birth 
weight and SGA associated infant morbidity and mortality. 
 
INTRODUCTION 
In spite of knowledge of the health risks of tobacco smoking and numerous programs 
aimed at getting people to quit, smoking continues to be quite common among the general 
population and pregnant women. Recent studies have estimated the rate of smoking to be 
approximately 14-24% among nonpregnant U.S. women of reproductive age.34,63,64 During 
pregnancy, these rates decrease to between 7-12%,3,34,64 and many infants remain exposed to 
the adverse effects of cigarette smoke in utero. 
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Maternal smoking is causally associated with intrauterine growth restriction, 1,3,5 and 
increases the risk of preterm birth and low birth weight.20,64-68 A recent population-based study 
found that newborns of active tobacco smokers compared to those of non-smokers were more 
likely to weigh less (3150±759 g vs. 3377±604 g, P<0.05).69 Infants born preterm, low birth 
weight or small for gestational age (SGA) have an increased risk of neonatal complications and 
infant mortality.70,71 Furthermore, low birth weight and SGA births have been implicated in 
contributing significantly to adult-onset disorders such as hypertension, type 2 diabetes, 
cardiovascular diseases and metabolic syndrome.72-74  Tobacco use in pregnancy increases the 
risks of future health complications,20,75,76 creates a burden for families,77 and increases health 
care cost.77-79 
The negative impact of smoking on folate metabolism and diet quality including folate 
intake has been well documented in the literature.9,10 Smokers have lower blood folate 
concentrations than nonsmokers.6,8,17 Low folate intake and reduced red blood cell (RBC) folate 
levels in the late pregnancy increase the risk of SGA birth and low birthweight.8,11 However, 
numerous studies suggest a possible benefit of maternal folate consumption or blood folate 
levels on birth weight.8,12,80 Clinical observations have shown that taking folic acid throughout 
pregnancy prevents the premature delivery of small-for-gestational-age infants.81 Furthermore, 
in a review of randomized clinical trials (RCTs) investigating the effect of folic acid 
supplementation on birth weight, a significant dose-response association between folate intake 
and birth weight was observed.32 
A reduction in low birth weight and SGA will significantly help reduce infant morbidity 
and mortality and curb associated healthcare cost. Tobacco exposure is a modifiable risk factor 
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that improves birth outcomes82,83; however, smoking cessation programs during pregnancy are 
associated with high failure rates especially in low-income subpopulations.61,62 Folic acid, a 
growth stimulating nutrient which is reduced in mothers who smoke during pregnancy is 
another modifiable protective factor that has been found to improve birth outcome in both 
pregnant women generally and in smokers. In the Generation R European study, Bakker et al23 
found that folic acid supplements might reduce some of the adverse effects of maternal 
smoking on fetal growth and neonatal outcomes. The researchers concluded that the results 
from their observational study should be considered hypothesis-generating and be confirmed 
using randomized controlled trials.23 
 Despite evidence of a causal association between smoking in pregnancy and 
intrauterine growth restriction,1-3,5 a plausible relationship between smoking and low maternal 
folate6-8,17 and a possibility of folic acid supplements improving birth outcomes among 
smokers,23 no experimental study has investigated the benefit of folic acid in reducing the 
adverse effects of maternal smoking on fetal outcomes. 
In this study, we examined the efficacy of higher-strength folic acid in combination with 
smoking cessation programs in preventing a reduction in fetal body size among smoking 
pregnant women. Primary data from a double-blinded randomized controlled trial which 
utilized validated tools and biomarkers were analyzed. We hypothesized that mothers on 
higher-strength folic acid versus standard of care folic acid would have infants with higher birth 
weight and lower risks of small for gestational age (SGA). 
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METHODS 
 
Trial Population and Design  
This was a randomized, double-blind, controlled clinical trial in which 345 smoking 
pregnant mothers underwent randomization. Eligible participants were randomly assigned in a 
1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or 4mg/day of folic acid 
(higher-strength). The folic acid tablets had exactly the same color, shape, size, and were 
packed in identical coded bottles. The code was the only distinguishable feature which was 
used to determine whether the bottle contained a 0.8 mg or 4 mg folic acid tablet. This code 
was concealed with patient ID labels. The physicians, laboratory staff, study investigators and 
study participants were masked to the treatment groups. 
Randomization was performed by a biostatistician through a computer-generated 
randomization schedule, using a permuted block design with a block size of 12. This type of 
design was chosen to allow balance in the number of participants in each group at the end of 
the clinical trial. The coded randomization schedule was properly stored in a sealed envelope 
within a locked file cabinet. In addition to the intervention, both study arms received 
preparations of multi-vitamins that did not contain folic acid and were enrolled in the smoking 
cessation program at the study site. 
Participants were recruited between 2010-2015 at the Genesis Clinic Tampa, a 
community health center affiliated with the Department of Obstetrics and Gynecology of the 
University of South Florida (USF). Almost all the pregnant women who receive antenatal care at 
the Genesis Clinic deliver their babies at the USF Department of Obstetrics and Gynecology at 
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Tampa General Hospital because of reduced cost of delivery for low-income women at this 
location. This made it easier to track patients and retrieve their birth data, thereby reducing 
loss to follow-up. 
Women were eligible for participation in the study if they were (1) current smokers (2) 
ages 18-44 years; (3) less than 21 weeks gestation as confirmed by last menstrual period; and 
(4) residents of Tampa, Florida, or a surrounding area, to facilitate follow-up and reduce 
attrition rate. To identify pregnant women who smoked at baseline, screening for cotinine was 
done using saliva (a biological marker for nicotine). Women who had at least a cotinine level of 
1 (detectable cotinine) were eligible for the study. Participants were excluded if there was 
evidence of an indication for chronic blood transfusion and treatment with anticonvulsant 
medication. Women receiving chronic blood transfusion may have inaccurate measures of 
folate RBC levels, due to transfused red blood cells (RBC).  Patients treated with anticonvulsants 
may have folic acid deficiency as side effects of the medication.37 Table A2.4. in Appendices 
shows the schedule of data collection, instruments, and procedures used in this trial. Study 
questionnaires and salivary cotinine laboratory assessments were completed during the three 
study visits. At delivery, cotinine level was further evaluated, and fetal body measurements 
were taken. 
Written informed consent was obtained from all the participating women before trial-
related procedures were initiated at screening and enrollment. Informed consent was available 
in both English and Spanish. The study was funded by the James and Esther King Biomedical 
Research Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987). The 
trial protocol was approved by the Institutional Review Board of the University of South Florida. 
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Smoking Cessation Program 
All women enrolled in the trial signed a contract stating they agreed to commit to 
quitting smoking, and attended at least one smoking cessation session at the study site for 
smoking mothers or called the Florida Quit Line. The counseling sessions focused on the 
following; (1) receipt of self-help materials and how to make a quit attempt, (2) effects of 
secondhand smoke, partners who smoke and tips on how to establish smoke-free homes and 
cars, (3) stress management and benefits of not smoking, and (4) prevention of smoking 
relapse. Women who persistently tested positive to salivary cotinine were referred by study 
personnel to Florida’s QuitLine, a toll-free telephone-based tobacco use cessation service. 
Additionally, all women were linked to community smoking cessation services such as the 
Hillsborough County Healthy Start program, a free, voluntary and intensive smoking cessation 
program. 
 
End-Point Measures 
The primary endpoint in this study was small for gestational age (SGA).  SGA was defined 
as infants weighing below the 10th percentile of birth weight for their gestational age using 
normalized growth curves.84 Gestational age was based on dating ultrasound at first prenatal 
visit and the date of delivery of the baby. The secondary outcome was birth weight measured in 
grams at delivery. 
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Covariates 
These variables which were used to describe the baseline characteristics of the study 
population include sociodemographic factors (such as maternal age, race, marital status, and 
insurance status), lifestyle factors (such as cotinine level, alcohol consumption, and maternal 
body mass index (BMI)), and perinatal factors such maternal depression, stress, gestational age 
and maternal chronic diseases such as hypertension and diabetes.    
Sociodemographic and lifestyle factors were extracted from participants’ medical 
records, specifically the American College of Obstetrics and Gynecology (ACOG) form. This form 
is routinely used at the study site to document mothers’ information such as demographic, 
obstetric and gynecologic history, and results of physical and laboratory examinations. 
Race/ethnicity was categorized into three groups: non-Hispanic black (black), non-Hispanic 
white (white), and other (includes Hispanic). Age was defined as both continuous and 
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized 
as either married or unmarried; the latter included divorced, separated and unknown marital 
status.  Health insurance was categorized as private or public/uninsured. BMI was calculated 
using maternal self-reported pre-pregnancy weight and height measured at enrollment. BMI 
was calculated as weight (kg)/ height (m)2 and categorized into normal (<25·0kg/m2), 
overweight (25·0–29·9kg/m2) and obese (≥30·0kg/m2). Although 5 women had BMI below 18.5 
(underweight), they were included in the normal BMI group due to limited sample. 
 Depression was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is 
a validated tool for assessing ante-natal and post-natal depressive symptoms depression 
measurement.44 Mothers who score above 12 or 13 on the scale are likely to be suffering from 
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depression.45 We dichotomized this variable as high and low, using a cut-off point of 12. Stress 
was measured using the Perceived Stress Scale (PSS-14) scale, which is a validated tool for 
comparisons between people in study samples.46 As a result, women who had a score equal to 
or greater than the mean stress score for the sample were classified as having high-stress 
levels, while those who had a score below the mean were classified as having low-stress levels. 
Cotinine was measured by a test of maternal saliva for the presence of cotinine with the 
use of a rapid semi-quantitative screening test called NicAlert (Jant Pharmacal Corporation, 
Encino, CA). Salivary cotinine analysis is the most sensitive and specific of the three types of 
cotinine measures.78 This method has a sensitivity of 99% and specificity of 82%. The cotinine 
test strip displays seven levels (0-6), each of which represents a range of salivary cotinine 
concentrations. Higher levels on the strip indicate a higher range of cotinine.  Based on the 
manufacturer’s guidelines, individuals with a reading of at least level 1 result are considered 
smokers. Cotinine level was also treated as a continuous variable in our analysis.    
 
Statistical Analysis 
The parent grant was designed with a sample size of 400 women and an expectation of 
following up 320 participants until delivery. These numbers were estimated from a sample size 
calculation conducted to evaluate the efficacy of higher-strength folic acid in combination with 
smoking cessation programs in preventing a reduction in the trial’s primary outcome; small for 
gestational age. The following were the assumptions used: (1) a type 1 error rate of 5%; (2) 
power of 80%; (3) an incidence of 14% SGA as reported by among mothers that receive services 
mostly from the study site; (4) an effect size of 2.0 based on the parent grant’s pilot data that 
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found that the percentage of DNA-hypomethylation in placental tissues from smoking mothers 
was 2.5 times that of non-smokers; (5) a 20% attrition rate. In this study, outcome data was 
available for 312 participants, and this translates to a power of 78%. 
We assessed the differences in the baseline sociodemographic, lifestyle and health-
related characteristics of study participants by their treatment groups. Means of continuous 
data were compared using independent t-tests or ANOVA, while categorical variables were 
compared using the chi-square test. Using the intention-to-treat (ITT) population, birth 
outcomes for all study participants were described using frequencies and percentages. ITT 
population includes all randomized participants in the groups to which they were randomly 
assigned, irrespective of their adherence to the treatment, regardless of the treatment they 
actually received, and regardless of withdrawal from treatment or deviation from the study 
protocol.85 All primary analyses were conducted on a modified intention-to-treat basis and 
included participants who completed the trial with an observed endpoint, irrespective of 
compliance to protocol. Excluded were abortions/miscarriages, fetal demise, and still births 
because the endpoints were not observed, and congenital anomalies or multiple births because 
growth potentials for those fetuses may not be comparable to normal singleton fetuses. 
Twenty-six cases (n=26) were excluded, therefore leaving the total participants eligible to be 
included in the modified intention-to-treat analyses as 319.  Two hundred and forty-six (n=246) 
women were followed until delivery at Tampa General Hospital, and additional birth data (such 
as birthweight, gestational age, and gender of the neonate) were retrieved from medical 
records during postnatal follow-up for 66 participants. For both of our primary and secondary 
endpoints, outcome data were obtainable for a total of 312 subjects, representing 97.8% of the 
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population eligible for inclusion in the modified intention-to-treat analysis. Due to loss to 
follow-up, data was unavailable for 2.2% (n=7) of the eligible population. 
 Since there were four repeated measures of cotinine level from participants during the 
trial, the decision was made to identify the unique paths of cotinine levels throughout the 
pregnancy. Group-based latent class trajectory model, a semiparametric method, used to 
discover patterns, was utilized. This approach offers a data-driven method to identify distinct 
individual patterns of a variable of interest and the corresponding probability of falling into 
each pattern, also known as the posterior probability.86 Trajectory analyses were conducted, 
and participants were then classified into groups based on their highest posterior probability. 
The fit of five models, with two to six subgroups, were compared by applying all linear 
terms and quadratic terms (Table A2.5 in Appendices).  Model 4 had the highest Bayesian 
information criterion (BIC), but the log Bayes factor approximation (2(∆BIC)) comparing the 
three-group model to the four-group model was low (4.4 and 3.8 for linear and quadratic terms 
respectively). According to the criteria for the log Bayes factor approximation,87 there is no 
strong evidence against the null three-group model when comparing the two models, so the 
three-group model has a better fit. Therefore, it appears that three groups is the optimal 
number of latent cotinine subgroups. We also determined the polynomial degree for each 
trajectory in the three-group model by investigating every permutation of both linear and 
quadratic terms ((Table A2.6 in Appendices). We sorted from the best to worst model, based on 
Bayesian information criterion (BIC). Consequently, model one was chosen as the best 
combination of polynomial degrees for the three-group cotinine model, namely high, moderate 
and low cotinine levels. The discriminated cotinine group identified was included in our 
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analyses as a group variable representing cotinine trajectory. All statistical tests were two-tailed 
with a type 1 error rate fixed at 5%. Statistical analyses were conducted in SAS (SAS Institute, 
Inc., Cary, North Carolina, version 9.4). 
 
Small for Gestational Age (SGA) 
The chi-square test was used to compare crude frequencies and percentages between 
maternal and fetal characteristics with respect to the outcome. Relative risks of having an SGA 
neonate among mothers who had the high dose treatment vs. standard dose was estimated 
using a log-binomial regression model.  Race was adjusted for in the model because it was not 
balanced across treatment groups at baseline. Cotinine group trajectory was also included in 
the model to account for possible changes in cotinine levels during the course of pregnancy. 
Relative risks (RR) and 95% confidence intervals reported. 
 
Birthweight 
This continuous variable was assessed for normality, and the distribution was close to 
symmetrical and assumed to be approximately normal (Fig A2.1 in Appendices). The measures 
of central tendency also showed that the mean, median and mode were very similar (data not 
shown). Independent t-tests and ANOVA were used to compare birth weight between the trial 
treatment groups and participants’ characteristics. Multiple linear regression analysis was 
conducted, adjusting for race and cotinine group trajectory. Mean differences and standard 
errors were reported. 
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RESULTS 
Figure 3.1 describes the enrollment and follow-up of the participants. A total of 345 
smoking pregnant women were enrolled in the trial; 171 women were randomly assigned to 
the high-dose folate and 174 to standard dose folate. Of these women, birth outcome data was 
available for 312 (90.4%), and this represents the number of participants included in the 
modified intention to treat (mITT) analysis. For the mITT population, 152 women were in the 
high-dose folate group and 160 in the standard dose folate group. 
In Table 3.1, we present the sociodemographic, lifestyle and health-related 
characteristics of study participants by folate dose treatment received. The baseline 
characteristics of the participants in the two groups were well matched with the exception of 
race. Women of ‘other’ race were more likely to be assigned to the standard of care. The mean 
(±SD) age of participants was 26.7 (±5.6) years, and the trial population was predominantly 
made up of single/divorced (90.1%) and women without insurance or on public insurance plans 
(95.1%). Approximately two-thirds of the population was either overweight or obese (67.7%), 
and about one-third had hypertension (34.3%) or diabetes (32.7%). 
Table 3.2 shows a description of the overall birth outcomes in the intention to treat 
population. The total number of live births was 312 (90.4%), and the incidence of SGA was 
21.4% (n=74). Among the mothers in the trial, SGA birth was recorded in 30 (17.5%) infants in 
the high-dose folate group and 44 (25.3%) in the low-dose folate group (P =0.079). There were 
marginal differences in SGA risk by treatment group but not in the rate of live births (P =0.427). 
In all modified intention-to-treat analyses conducted in this study, we excluded 26 participants 
(7.5%) for the following reasons: pregnancies that ended up in induced abortion/miscarriage 
38 
 
(n=12), congenital anomaly (n=2), fetal demise (n=5), stillborn (n=3), and multiple gestations 
(n=4). There were no statistical differences in the rate of excluded birth outcomes and live 
births by treatment group (Table 3.2). 
Figure 3.2 illustrates the longitudinally-derived cotinine trajectories for trial participants. 
We discriminated three distinct groups of maternal cotinine velocities; one with a consistently 
high level of cotinine, another with a low level and the third group with moderate cotinine level 
but a marked decline towards the end of gestation. Approximately 18.9%, 48.3% and 32.8% of 
the study participants were classified respectively into the groups stated above. At the end of 
the study, only 3.0% of the women with cotinine data at delivery (n=8) had stopped smoking 
(cotinine level of zero). 
In Table 3.3, we present the results of the maternal and fetal characteristics of the study 
participants by crude mean birthweight.  The overall mean (±SD) infant weight at birth was 
3059.0g (±640.2), and there were significant differences by treatment, cotinine group and illicit 
drug use (P <0.05). Mothers who received high-dose folate, had low cotinine trajectory and 
never abused drugs during pregnancy had babies with higher birth weight. There were no 
significant differences in birthweight by other selected characteristics.   
In Table 3.4, we present the results from the multivariable linear regression of the effect 
of treatment on birthweight. Smokers on high-dose folate during pregnancy had infants with a 
140.38g higher birthweight than their counterparts on standard dose folate (P =0.047). 
Compared to mothers with low cotinine levels, mothers with high or moderate cotinine levels 
had babies with approximately 435g and 205g significantly lower birth weight. Additionally, 
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babies of black mothers and mothers of ‘other’ race weighed over 200g less than infants born 
to white mothers (P <0.05).  
A comparison of maternal sociodemographic and health-related characteristics by SGA 
within the trial population is presented in Table 3.5. Mothers with SGA babies were more likely 
to be older, have higher baseline cotinine level, use illicit drugs in pregnancy and have a 
consistently high/moderate cotinine level during pregnancy (P <0.05). There were no significant 
differences in SGA by other selected maternal and fetal characteristics.   
In Table 3.6, we present results from the log-binomial model estimating the risks of SGA. 
Smokers during pregnancy who were assigned high-dose folate had a 31.0% lower risk of having 
babies with SGA compared to their counterparts on the standard-dose (adjusted relative risk-
ARR=0.69, 95% CI: 0.46–1.03; (P =0.073)). Black mothers had approximately 51% higher risk of 
SGA babies than white mothers, and this association was marginally significant (ARR=1.51, 95% 
CI: 0.99–2.31, P =0.058). Additionally, mothers with high and moderate cotinine trajectory 
levels were 2.5 times and 1.9 times respectively more likely to have SGA babies than mothers 
with low cotinine levels.  
 
DISCUSSION 
In this randomized clinical trial, we examined the efficacy of 4mg/ day dose of higher-
strength folic acid versus 0.8mg/ day dose of folic acid (standard dose) in reducing the risk of 
small for gestational age (SGA) and increasing birth weight among low-income mothers who 
smoked during pregnancy. We observed a 31% lower risk of small for gestational age (SGA) 
birth among mothers on high dose folate, with a trend towards statistical significance (P 
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=0.073). Mothers on high-dose folate had babies with a significantly higher birth weight (140g) 
than those on standard folate dose in the adjusted model. Another finding in our trial was a 
dose-response effect of cotinine trajectory on both an increase in the risk of SGA and a 
decrease in birth weight. As in other studies, black mothers had infants who weighed 
significantly lower at birth and had increased risk of SGA than white mothers.88, 89 It is worthy of 
note that no prior experimental study has been conducted to investigate the efficacy of folic 
acid on improving birth outcomes among smokers.  
Previous observational studies have identified a protective effect of folic acid 
supplements on the risk of SGA among women of reproductive age, in general. 23,90-92 Similar to 
our findings, a population-based cohort study found in their subgroup analyses of women who 
continued to smoke during pregnancy, that participants who took no folic acid supplement had 
a 29% higher odds of SGA than their counterparts who took 0.4–0.5 mg/day folic acid 
supplement [odds ratio 1.29 (95 % confidence interval 0.69, 2.42)]. It is important to note that 
Bakker and colleagues23 compared no folate supplement to standard of care dose in their study 
while we compared standard of care dose to higher strength folate. Even though our findings 
and those of Bakker et al23 were not statistically significant, they suggest that the adverse effect 
of maternal tobacco smoking on SGA may be reduced by folic acid supplementation. Unlike the 
Bakker et al23 study that used self-report to assess folic acid intake, we randomly assigned 
women to folic acid treatment, thereby reducing the possibility of misclassification and type 2-
error.  In our trial, folic acid treatment was commenced in the first trimester/ mid-pregnancy 
(less than 21 weeks gestation), and this might account for a lower effect of treatment on SGA 
risk. A recent meta-analysis of cohort studies reported that folic acid supplementation initiated 
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preconceptionally was more protective against SGA births than supplementation started after 
conception.90 Another systematic review and meta-analysis found that folate supplementation 
only significantly reduces the risk of SGA birth if commenced before conception.92 
In several published works, including a systematic review of randomized clinical trials, 
significant positive associations between folate intake and birth weight were observed.8, 32, 80, 
92,93 However, these studies included women of reproductive age in general; smokers and non-
smokers, limiting our ability to compare findings. The result from the current study 
demonstrated a positive effect of high dose folate on birth weight among smokers during 
pregnancy. Similar to our findings, Bakker et al23 found a mean difference of 112g in birth 
weight among a subgroup analysis of smokers who did not use folic acid supplement vs. those 
who used 0.4mg/day in the periconceptional period [-112 (95 % confidence interval -187, -
370)]. Our study builds on this observational study that compared no folic vs. folic acid 
supplement and provides evidence that higher dose folate may increase birth weight among 
women who smoke in pregnancy.  
We observed a dose-response gradient of cotinine trajectory groups on the risk of SGA 
and low birth weight.  Higher cotinine group was associated with worse birth outcomes. This 
finding is novel; studies have generally not examined the effect of cotinine trajectory on birth 
outcomes among smokers. Previous studies that have investigated the effect of smoking on 
birth outcomes assessed tobacco exposure at one time point.67,94 or at multiple time points20 
without taking into consideration cotinine groups or patterns. Similar to the dose-response 
effect observed in our study, previous observational studies that utilized cross-sectional 
assessments of smoking reported an increase in adverse birth outcomes by cotinine 
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concentrations.94 Maintaining lower levels of smoking among women of reproductive age who 
are unable to quit seems beneficial in reducing SGA birth and low birth weight. 
Infants of Black mothers who smoked during pregnancy had a higher risk of small SGA 
and lower birth weight compared to infants of their white counterparts. Because of the limited 
number of SGA cases, we could not access the modification effect of treatment on the 
association between race and SGA. Even though our trial was restricted to smokers, our 
findings are similar to previous reports in the United States that black infants, in general, have 
worse birth outcomes. 88-89 They have consistently had lower birth weight than Whites, and this 
disparity has remained for decades.89, 95 Studies have suggested that these White-Black 
disparities are due to pathological, rather than genetic restrictions in fetal growth.96,97 The 
adverse intrauterine environment in which black fetuses grow might reflect prolonged and 
accumulated experiences of racial discrimination or other sources of psychological stress.96-98 
In this trial, we did not observe significant differences in the percentages of mothers 
with adverse birth outcomes such as spontaneous abortion and stillbirth between the 
treatment groups in a bivariate analysis (P >0.500). Folic acid is a water-soluble Vitamin B 
substance and is safe in pregnancy at the dose used in the trial.100 Doses as high as 5mg/day 
and greater have been used in previous growth studies with no apparent adverse effects. 93,99 
However, an epigenetic study has demonstrated possible effects of folic acid supplementation 
on the genome of the offspring.101 Thus, long-term follow-up of the infants of study participants 
exposed to higher-strength folate would be beneficial. Close monitoring for safety and adverse 
events associated with higher strength folate in future studies will be necessary. Overall, larger 
studies will be required to confirm or refute our findings and examine the effect of high 
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strength folic acid in reducing adverse birth outcomes especially among high-risk subgroups 
such as Black women. 
This study has several important limitations. First, we did not assess or control for the 
effect of diet, a possible confounder in this study. However, randomization was conducted and 
there is reduced likelihood of differences in the diet by treatment groups. Even though we 
estimated a power of 78% to detect a difference in SGA risk, the confidence interval was quite 
narrow indicating precision and stability of the estimates. As with most clinical trials, the 
generalizability of our findings to an external population is an issue. Voluntary participants in 
studies are usually different from nonparticipants. However, our results may be applicable to 
low-income women who smoke during pregnancy. 
There are numerous strengths of this trial. The use of double-blind, randomized clinical 
trial allows for causal inference. Even though we had a relatively high percentage of women lost 
to follow-up, we were able to retrieve their outcome data from medical records, thereby 
minimizing information bias due to follow up. The efficacy of folate in the modified intention-
to-treat population (31.0%), may more closely represent the effectiveness under real-world 
conditions. A per-protocol analysis, a type of analyses which exclude participants who deviate 
from the protocol could have produced more significant findings. To our knowledge, this is the 
first randomized control trial to report the effect of high strength folic acid in combination with 
enrollment in smoking cessation program in preventing adverse birth outcomes among 
smokers in pregnancy. 
In conclusion, higher strength folic acid supplementation may have the potential to offer 
smoking pregnant women a safe, easy and convenient option for reducing their risk of adverse 
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birth outcomes.  The achievement of a higher infant birth weight in smoking mothers on high 
strength folic acid is significant for this high-risk group.  Additionally, the possibility of a 
decrease in SGA births by approximately 31% would be huge considering the number of cases 
of SGA births that can be prevented, and the subsequent reduction of burden on families and 
the health care system. Higher strength folic acid supplementation in pregnant women who 
smoke might be a cost-effective way to improve birth outcomes and reduce low birth weight 
and SGA associated infant morbidity and mortality. 
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Figure 3.1. Enrollment, randomization, and follow-up of participants 
 
 
345 women underwent 
randomization 
Baseline: 171 were 
assigned to receive 4mg 
of folic acid once daily 
Baseline: 174 were 
assigned to receive 
0.8mg of folic acid once 
daily 
Visit 2: 149 participants 
attended follow-up visit 
 
Visit 2: 145 participants 
attended follow-up visit 
Visit 3: 145 participants 
attended follow-up visit 
Visit 3: 137 participants 
attended follow-up visit 
 
19 Lost to follow-up  
7 Fetal loss  
 
127 completed study 
with birthweight data 
119 Completed study 
with birthweight data  
8 Lost to follow-up 4 Lost to follow- up 
13 Lost to follow-up 
or delivered outside 
of center, 2 Fetal 
loss, 1 Congenital 
anomaly, 2 Multiple 
gestation 
11 Lost to follow-up 
or delivered outside 
of center, 4 Fetal 
loss, 1 Congenital 
anomaly, 2 Multiple 
gestation 
18 Lost to follow 
7 Fetal loss 
 
152 Total participants 
with birthweight data 
were included in the 
modified intention to 
treat analysis 
 
 
160 Total participants 
with birthweight data 
were included in the 
modified intention to 
treat analysis 
 
33 Birthweight data 
retrieved during 
postnatal follow-up 
 
 
33 Birthweight data 
retrieved during 
postnatal follow-up 
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Table 3.1. Baseline socio-demographic, lifestyle and health-related characteristics of all 
randomized study participants by folate treatment (n=345) 
Variables   High-Dose 
Folate (N=171) 
Standard Dose 
Folate (N=174) 
P-valueb 
 Na (%) Count (%) Count (%)  
Age in years  26.7±5.6 26.4±5.1 27.3±5.8 0.1035 
Gestational age  12.3±3.9 12.4±3.9 12.2±3.9 0.5721 
Baseline Cotinine  2.9±1.4 3.0±1.5 2.9±1.4 0.3535 
Race       0.0274 
         White 148 (42.9) 78 (45.6) 70 (40.2)  
         Black         140 (40.6) 74 (43.3) 66 (37.9)  
         Other 57 (16.5) 19 (11.4) 38 (21.8)  
Marital Status       0.255 
          Married   34 (9.8) 20 (11.7) 14 (8.05)  
          Single/ Divorced 311 (90.1) 151 (88.3) 160 (91.9)  
Spanish Speaking        
         Yes 21 (6.1) 8 (4.7) 13 (7.5) 0.2780 
         No 324 (93.9) 163 (95.3) 161 (92.5)  
Insurance       0.4336 
         Public/None 328 (95.1) 161 (94.1) 167 (96.0)  
         Private 17 (4.9) 10 (5.9) 7 (4.0)  
 BMI        
         Not overweight 111 (32.4) 53 (31.0) 58 (33.7) 0.1239 
         Overweight 85 (24.8) 36 (21.0) 49 (28.5)  
         Obese 147 (42.9) 82 (47.9) 65 (37.7)  
Alcohol Use        
        Yes 30 (9.5) 18 (11.2) 12 (7.6) 0.2727 
         No 287 (90.5) 142 (88.7) 145 (92.4)  
Illicit Drug Use        
         Yes 94 (31.0) 50 (32.9) 44 (29.1) 0.4798 
          No 209 (69.0) 102 (67.1) 107 (70.9)  
Stress Score        
         High 191 (55.4) 95 (55.6) 96 (55.2) 0.9498 
          Low 154 (44.6) 76 (44.4) 78 (44.8)  
Depression Score        
         High 63 (18.3) 31 (18.1) 32 (18.4) 0.9498 
         Low 282 (81.7) 140 (81.9) 142 (81.6)  
Hypertension        
        Yes 113 (34.3) 54 (33.1) 59 (35.5) 0.6449 
         No 216 (65.7) 109 (66.9) 107 (64.5)  
                                                                                                                                Continued on next page 
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Table 3.1. (Continued) 
Variables 
 
High-Dose 
Folate (N=171) 
Standard Dose 
Folate (N=174) 
P-valueb 
Diabetes        
         Yes 108 (32.7) 52 (31.9) 56 (33.5) 0.7522 
         No 222 (67.3) 111 (68.1) 111 (66.5)  
Heart Disease        
         Yes 42 (12.8) 22 (13.5) 20 (12.1) 0.7093 
         No 286 (87.2) 141 (86.5) 145 (87.9)  
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Table 3.2. Birth outcomes for study participants in the intention-to-treat population (n=345) 
Event High-Dose Folate  
(N= 171) 
Standard Dose Folate  
(N= 174) 
P-value 
                                                no. of participants (%)  
Small for Gestation Age 30 (17.5)  44 (25.3) 0.0798 
Singleton live birth 152 (88.9) 160 (91.9) 0.4272 
Induced abortion/miscarriage 6 (3.5) 6 (3.4) 0.9755 
Congenital anomaly 1 (0.6) 1 (0.6) 1.0000 
Fetal demise 3(1.7) 2 (1.1) 0.6830 
Still born 2 (1.2) 1 (0.6) 0.6206  
 
Multiple gestation 2 (1.2) 2 (1.1) 1.0000 
*Complete loss to follow-up 5 (2.9) 2 (1.1) 0.2791 
*Indicates delivery records that were not available or retrievable. 
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Figure 3.2. Longitudinal-derived cotinine trajectories in the modified intention-to-treat 
population (n=319) 
Each straight line reflects separate cotinine trajectory: 1-low level; 2-moderate level; and 3-high 
level. 
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Table 3.3. Maternal and fetal characteristics of the trial sample by mean birthweight (N = 312) 
Variables Mean (SD) p-value 
Overall 3059.0 (640.2)  
Treatment  0.0457 
    High-dose 3133.3 (608.5)  
     Low- dose 2988.5 (663.2)  
Maternal Age  0.2679 
     18–24 2928.7 (802.9)  
     25–34 3073.1 (631.0)  
     ≥35 2944.0 (711.1)  
Maternal Race  0.0608 
    Non-Hispanic white 3150.9 (625.5)  
    Non-Hispanic black 3012.2 (568.8)  
    Other 2928.7 (802.9)  
Marital status  0.0890 
     Married 3235.3 (684.1)  
     Unmarried 3037.5 (632.6)  
Insurance Type  0.9946 
    Private 3054.3 (390.1)  
    Public /Uninsured 3055.0 (648.4)  
Trimester   0.4665 
     First  3035.5 (684.9)  
     Second  3087.8 (581.8)  
Body mass index  0.1372 
     <25 2983.5 (581.4)  
     25–30 3014.4 (730.1)  
     >30 3142.7 (621.6)  
Cotinine group  0.0015 
      Low 3175.7 (613.7)  
      Moderate 3028.8 (660.7)  
      High 2819.4 (601.2)  
Depression Score  0.0804 
     <12 3089.3 (627.1)  
     ≥12 2926.4 (684.9)  
Perceived Stress Score  0.1788 
    Low 3111.9 (556.6)  
    High 3016.0 (699.6)  
                                                                                                                                               Continued on next page 
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Table 3.3. (Continued) 
Alcohol Use  0.2156 
        Yes 3097.8 (617.9)  
         No 2963.6 (706.6)  
Illicit Drug Use  0.0034 
         Yes 2909.4 (686.4)  
          No 3159.0 (582.8)  
Hypertension  0.3286 
        Yes 3051.5 (618.2)  
         No 3098.6 (625.4)  
Diabetes  0.5634 
         Yes 3107.3 (606.8)  
         No 3075.2 (619.6)  
Heart Disease  0.8515 
         Yes 3061.6 (620.3)  
         No 3082.2 (625.4)  
Gender of child  0.3448 
   Female 3039.4 (543.4)  
    Male 3111.4 (729.9)  
Trimester=trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group 
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Table 3.4. Adjusted effect of folate treatment on birthweight (g) among trial population 
(n=312) 
Variables β  SE p-value 
Treatment    
      High dose 140.39 70.52 0.0474 
      Low dose ref - - 
Cotinine group    
       High -434.90 79.45 <0.0001 
       Moderate  -205.40 99.78 0.0102 
        Low ref - - 
Race    
       Black -224.01 78.98 0.0049 
       Other  -264.94 103.43 0.0109 
       White ref - - 
*Adjusted for cotinine group trajectory and race. β= Estimate; SE= Standard error; ref= Reference group. 
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Table 3.5. Maternal and infant characteristics by small for gestational age (n=312). 
Variables  SGA (N=72) NO SGA (N=240) P-valueb 
 Count (%) Count (%)  
Age in years  28.5±5.4 26.6±5.7 0.0095 
Gestational age  38.3±1.9 38.4±2.6 0.7758 
Baseline Cotinine  3.5±1.5 2.8±1.4 0.0007 
Race     0.5069 
         White 29 (40.3) 107 (44.6)  
         Black         33 (45.8) 92 (38.3)  
         Other 10 (13.9) 41 (17.1)  
Marital Status     0.1301 
          Married 4 (5.6) 30 (12.5)  
          Single/ Divorced 68 (94.4) 210 (87.5)  
Insurance     0.5414 
         Public/None 67 (93.1) 228 (95.4)  
         Private 5 (6.9) 11 (4.6)  
 BMI     0.4874 
         Not overweight 26 (36.6) 72 (30.1)  
         Overweight 19 (26.8) 62 (25.9)  
         Obese 26 (36.6) 105 (43.9)  
Alcohol Use     0.6729 
        Yes 6 (10.7) 17 (8.8)  
         No 17 (89.3) 175 (91.2)  
Illicit Drug Use     0.0141 
         Yes 25 (43.9) 52 (29.1)  
          No 32 (56.1) 142 (70.9)  
Cotinine Group     0.0044 
         High 20 (27.8) 36 (15.0)  
         Moderate 30 (41.7) 82 (34.2)  
        Low 22 (30.6) 122 (50.8)  
Stress Score      
         High 42 (58.3) 130 (54.2) 0.5330 
          Low 30 (41.7) 110 (45.8)  
Depression Score     0.2117 
         High 17 (23.6) 41 (17.1)  
         Low 55 (76.4) 199 (82.9)  
Hypertension      
        Yes 22 (37.9) 68 (34.0) 0.5802 
         No 36 (62.1) 132 (66.0)  
                                                                                                                                                Continued on next page 
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Table 3.5. (Continued) 
 
Diabetes      
         Yes 21 (36.2) 65 (32.3) 0.5816 
         No 37 (63.8) 136 (67.6)  
Heart Disease      
         Yes 10 (16.9) 28 (14.1) 0.5938 
         No 49 (83.1) 170 (85.9)  
Infant Gender      
       Female 38 (59.4) 107 (48.4) 0.1225 
        Male 26 (40.6) 114 (51.6)  
*Plus-minus values are means ±SD.  a. some cell numbers do not sum up to 345. b significant p values are in bold. 
SGA= small for gestational age.  
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Table 3.6. Adjusted effect of folate treatment on small for gestational age among trial 
population (n=312) 
Variables Relative Risk 95% C.I 
Treatment   
      High dose 0.69 0.46- 1.03 
      Low dose ref - 
Race   
      Black 1.51 0.99- 2.31 
      Other 1.01 0.54- 1.90 
       White ref - 
Cotinine group   
       High 2.51 1.50-4.23 
       Moderate  1.92 1.17- 3.14 
        Low ref - 
Adjusted for cotinine group trajectory and race. C.I= confidence interval; Estimates in bold are significant at p-
value <0.05.  
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CHAPTER FOUR: 
 
 
MANUSCRIPT 3: EFFICACY OF HIGHER-STRENGTH FOLIC ACID ON FETAL BRAIN GROWTH AND 
DEVELOPMENT AMONG WOMEN WHO SMOKED DURING PREGNANCY 
 
ABSTRACT 
The role of folic acid supplementation in fetal head growth among women of 
reproductive age is well documented in observational studies. However, research on the effect 
of folate supplementation among high-risk subgroups, such as women who smoke during 
pregnancy, is minimal. Furthermore, no experimental study has been conducted to examine 
this relationship. In this study, we investigated the efficacy of high strength folic acid 
supplementation vs. standard dose on increasing prenatal fetal brain growth, measured by 
head circumference, brain weight, and brain-body ratio. 
A randomized, double-blind, controlled clinical trial involving 345 smoking pregnant 
mothers was conducted. Participants were recruited between 2010-2015 at the Genesis Clinic 
Tampa, a community health center affiliated with the Department of Obstetrics and 
Gynecology of the University of South Florida (USF). Those who met the eligibility criteria were 
randomly assigned in a 1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or 
4mg/day of folic acid (higher-strength). They were also enrolled in a smoking cessation 
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program. The two-level linear growth model, a type of multilevel modeling, was used for 
assessing treatment effect and factors that predict intrauterine increase in head circumference 
over time. Multiple linear regression analyses were conducted to estimate the effect of higher-
strength folic acid on head circumference at birth, fetal brain weight, and fetal brain-to-body 
ratios (BBR). 
Mothers who received higher strength dose of folate had infants with a 1.18mm larger 
mean head circumference compared to infants of mothers who received the standard folate, 
but this difference was subtle and not statistically significant (P = 0.2762). High-dose folate also 
had no significant effect on head circumference and brain weight in our trial sample. However, 
the BBR of infants of mothers who received high-dose treatment was 0.33 percentage-point 
lower than for infants of mothers who received the standard dose of folate (P =0.044). 
In conclusion, smokers in pregnancy may benefit from folate supplementation in 
reducing the risk of having infants with impaired brain-body proportionality. A decrease in the 
proportion of infants with impaired BBR might contribute to a reduction in morbidity and 
health care cost associated with future neurocognitive disorders. 
 
INTRODUCTION 
A relatively large literature addresses the role of maternal smoking on fetal 
development20,65 67,68 and the developing brain is possibly the most sensitive organ to nicotine 
exposure.102 Nicotine readily crosses the placenta into the fetal serum and brain,103 and has 
been found to be neurotoxic.104 Maternal tobacco exposure is associated with reduced head 
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circumference,20,21,105,106 altered indicators of infant body proportionality such as brain-to-body 
weight ratio (BBR),107 and neurocognitive developmental problems in the offspring.108-110 
Though smoking cessation before mid-pregnancy may result in complete elimination of 
smoking-related deficits in infant head circumference and BBR,105,107 many mothers find it 
difficult to quit; thus, exposing their unborn babies to the harmful effect of tobacco. 
One likely mechanism of action of maternal smoking on adverse fetal outcomes is 
through a reduction in the concentration and activity of maternal folic acid reserve.11,15,28 
Smokers are more likely to consume fewer folate-rich diets and have impaired folate 
metabolism.13,28-30 Low maternal folate levels reduce the bioavailability of folate to the 
developing fetus, resulting in impaired growth. 111 Previous studies provide some evidence that 
prenatal folate deficiency might have an adverse effect on global fetal brain growth,112 
however, folate supplementation in early pregnancy may increase head circumference at 
birth112 and reduce neurodevelopmental disorders in offspring. 108, 113 
The role of folic acid supplementation and folate concentrations in fetal head growth 
among women of reproductive age is well documented. 112,114 However, research on the effect 
of folate supplementation among a high-risk subgroup such as women who smoke during 
pregnancy is minimal. Furthermore, no experimental study has been conducted to examine this 
relationship. In this study, we investigated the efficacy of high strength folic acid vs. standard 
dose folic acid on increasing prenatal brain growth. Specifically, the outcomes were head 
circumference, brain weight and brain-body ratio, a measure of brain-body proportionality 
derived from head circumference. Head circumference is a non-invasive proxy for fetal brain 
growth and development,114 and is closely correlated to brain volume. 115,116 In this study, we 
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hypothesized that among smoking mothers enrolled in a smoking cessation program, higher 
strength folic acid treatment is associated with increased fetal brain growth. 
 
METHODS 
 
Trial Population and Design  
This was a randomized, double-blind, controlled clinical trial in which 345 smoking 
pregnant mothers underwent randomization. Eligible participants were randomly assigned in a 
1:1 ratio to receive either 0.8mg/day of folic acid (standard of care) or 4mg/day of folic acid 
(higher-strength). The folic acid tablets had exactly the same color, shape, size, and were 
packed in identical coded bottles. The code was the only distinguishable feature which was 
used to determine whether the bottle contained a 0.8 mg or 4 mg folic acid tablet. This code 
was concealed with patient ID labels. The physicians, ultrasound technicians, laboratory staff, 
study investigators and study participants were masked to the treatment groups.  
Randomization was performed by a biostatistician through a computer-generated 
randomization schedule, using a permuted block design with a block size of 12. This type of 
design was chosen to allow balance in the number of participants in each group at the end of 
the clinical trial. The coded randomization schedule was properly stored in a sealed envelope 
within a locked file cabinet. In addition to the intervention, both study arms received 
preparations of multi-vitamins that did not contain folic acid and were enrolled in the smoking 
cessation program at the study site. 
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Participants were recruited between 2010-2015 at the Genesis Clinic Tampa, a 
community health center affiliated with the Department of Obstetrics and Gynecology of the 
University of South Florida (USF). Almost all the pregnant women who receive antenatal care at 
the Genesis Clinic deliver their babies at the USF Department of Obstetrics and Gynecology at 
Tampa General Hospital because of reduced cost of delivery for low-income women at this 
location. This made it easier to track patients and retrieve their birth data, thereby reducing 
loss to follow-up.  
Women were eligible for participation in the study if they were (1) current smokers (2) 
ages 18-44 years; (3) less than 21 weeks gestation as confirmed by last menstrual period; and 
(4) residents of Tampa, Florida, or a surrounding area, to facilitate follow-up and reduce 
attrition rate. To identify pregnant women who smoked at baseline, screening for cotinine- a 
biological marker for nicotine was done using saliva. Women with detectable cotinine levels of 
1 or more were confirmed eligible for the study. Participants were excluded if there was 
evidence of an indication for chronic blood transfusion and generalized seizure disorder treated 
with anti-convulsant medication. Women receiving chronic blood transfusion may have 
inaccurate measures of folate RBC levels, due to transfused red blood cells (RBC).  Additionally, 
patients treated with anticonvulsants may have folic acid deficiency as side effects of the 
medication.37 Table A2.4 in Appendices shows the schedule of data collection, instruments, and 
procedures used in this trial. Fetal ultrasounds, study questionnaires, and salivary cotinine 
laboratory assessments were completed during the three study visits. At delivery, cotinine level 
was further evaluated, and fetal body measurements were taken. 
61 
 
Written informed consent was obtained from all the participating women before trial-
related procedures were initiated at screening and enrollment. Informed consent was available 
in both English and Spanish. The study was funded by the James and Esther King Biomedical 
Research Program, Florida Department of Health (grant numbers 4KB03 and 1KG14-33987). The 
trial protocol was approved by the Institutional Review Board of the University of South Florida. 
 
Smoking Cessation Program 
All women enrolled in the trial signed a contract stating they agreed to commit to 
quitting smoking, and attended at least one smoking cessation session at the study site for 
smoking mothers or called the Florida Quit Line. The counseling sessions focused on the 
following; (1) receipt of self-help materials and how to make a quit attempt, (2) effects of 
secondhand smoke, partners who smoke and tips on how to establish smoke-free homes and 
cars, (3) stress management and benefits of not smoking, and (4) prevention of smoking 
relapse. Women who persistently tested positive to salivary cotinine were referred by study 
personnel to Florida’s QuitLine, a toll-free telephone-based tobacco use cessation service. 
Additionally, all women were linked to community smoking cessation services such as the 
Hillsborough County Healthy Start program, a free, voluntary and intensive smoking cessation 
program. 
 
End-Point Measures 
The outcomes were prenatal fetal brain growth defined as (1) rates of growth in intrauterine 
ultrasound measure of head circumference (growth velocity); and (2) three different measures 
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of cumulative head circumference growth (head circumference at birth, fetal brain weight, and 
fetal brain-to-body ratios (BBR)). The serial ultrasound measurements of head circumference 
(HC) were taken during the three expected study visits using standardized ultrasound 
procedures. Some women had more than three ultrasound procedures, due to request from 
healthcare providers, while some had fewer procedures due to no-show or loss to follow-up. 
Intrauterine HC was measured to the nearest millimeter on a transverse view of the fetal head 
in a plane showing both thalami and the third ventricle. The second outcome, head 
circumference at birth was measured to the nearest centimeter using a measuring tape. The 
third outcome, fetal estimated brain weight was derived from the National Institute of 
Neurological and Communicative Disorders and Stroke’s Collaborative Perinatal Project and was 
calculated using this formula: [0.037 × head circumference (cm) 2.57].117 The last outcome, the 
brain-to-body ratio (BBR) was defined as the percentage of the infant’s birth weight that is 
estimated to occupy the brain is a function of the head circumference. The BBR is calculated as 
100 × the ratio of the infant’s estimated brain weight to its birth weight and is expressed as BBR 
= 100 × [0.037 × head circumference (cm) 2.57] /birth weight (g). A high BBR indicates a higher 
percentage of birth weight residing in the brain, while a lower BBR suggests a lower fraction of 
birth weight residing in the brain.107 The typical values for healthy infants have been estimated 
to be 9-10%.107 Furthermore, higher BBR indicates larger brain weight for a given head 
circumference and is associated with small-for-gestational-age infants.116 
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Covariates 
Based on prior knowledge, a number of maternal and infant characteristics were 
considered as potential confounding factors due to their demonstrated association with fetal 
brain development. These include sociodemographic factors (such as maternal age, race, 
marital status, and insurance status), lifestyle factors (such as cotinine level, alcohol 
consumption, dietary folate and maternal body mass index (BMI)), and perinatal factors such 
maternal depression, stress, gestational age and maternal chronic diseases such as 
hypertension and diabetes. Gestational age (GA) at delivery, a measure of duration of the 
pregnancy in weeks, was based on dating ultrasound at first prenatal visit and the date of 
delivery of the baby. 
Sociodemographic and lifestyle factors were extracted from participants’ medical 
records, specifically the American College of Obstetrics and Gynecology (ACOG) form. This form 
is routinely used at the study site to document mothers’ information such as demographic, 
obstetric and gynecologic history, and results of physical and laboratory examinations. 
Race/ethnicity was categorized into three groups: non-Hispanic black (black), non-Hispanic 
white (white), and other (includes Hispanic). Age was defined as both continuous and 
categorical variable (grouped as 18-14, 25-34 and ≥35 years). Marital status was dichotomized 
as either married or unmarried, the latter included divorced, separated and unknown marital 
status.  Insurance (health insurance) was categorized as private or public/uninsured. BMI was 
calculated using maternal self-reported pre-pregnancy weight and height measured at 
enrollment. BMI was calculated as weight (kg)/ height (m)2 and categorized into normal 
(<25.0kg/m2), overweight (25.0–29.9kg/m2) and obese (≥30.0kg/m2). Although 5 women had 
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BMI below 18.5 (underweight), they were included in the normal BMI group due to limited 
sample. Dietary folate was assessed using a proxy, maternal red blood cell (RBC) folate 
concentration at study baseline. RBC folate was measured using enzyme-linked immunosorbent 
assay (ELISA). This was the preferred folate biomarker because of its advantages of long-term 
stability and reduced susceptibility to sudden changes in diet.19 Folate level was defined as a 
continuous variable.  
Depression was assessed using the Edinburgh Postnatal Depression Scale (EPSD). This is 
a validated tool for assessing ante-natal and post-natal depressive symptoms depression 
measurement.44 Mothers who score above 12 or 13 on the scale are likely to be suffering from 
depression.45 We dichotomized this variable as high and low, using a cut-off point of 12. Stress 
was measured using the Perceived Stress Scale (PSS-14) scale, which is a validated tool for 
comparisons between people in study samples.46 As a result, women who had a score equal to 
or greater than the mean stress score for the sample were classified as having high-stress 
levels, while those who had a score below the mean were classified as having low-stress levels.  
Cotinine was measured by a test of maternal saliva for the presence of cotinine with the 
use of a rapid semi-quantitative screening test called NicAlert (Jant Pharmacal Corporation, 
Encino, CA). Salivary cotinine analysis is the most sensitive and specific of the three types of 
cotinine measures.78 This method has a sensitivity of 99% and specificity of 82%. The cotinine 
test strip displays seven levels (0-6); with each level representing a range of cotinine 
concentrations. Based on the manufacturer’s guidelines, individuals with a reading of at least a 
level 1 result are considered smokers. With increasing level of cotinine, cotinine concentration 
increases. Cotinine level was treated as a continuous variable in our analysis. 
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Statistical Analysis 
The parent grant was designed with a planned sample of 400 women with 200 in each 
intervention group. This was the estimated number from a sample size calculation conducted to 
evaluate the efficacy of higher-strength folic acid in combination with smoking cessation 
programs in preventing a reduction in the trial’s primary outcome; small for gestational age. 
However, a total of 100 (50 smoking mothers in each treatment arm) was the estimated sample 
size required to determine whether higher-strength folic acid will improve fetal brain growth. 
This was based on the following assumptions: a type 1 error rate of 5%, power of 80%, a mean 
biparietal diameter (BPD) of 95.0mm (SD±2.5) at term for infants of non-smokers based on BPD 
reference values at the study site, and a 50% reduction in the rate of loss of fetal brain 
growth.105 A total of 345 women were enrolled, indicating sufficient power to find a treatment 
effect on fetal brain growth if one exists.  
Descriptive statistics were conducted for all variables examined. We assessed the 
differences in the baseline sociodemographic, lifestyle and health-related characteristics of 
study participants by their treatment groups. Means of continuous data were compared using 
independent t-tests or ANOVA, while categorical variables were compared using the chi-square 
test. Using the intention-to-treat population, birth outcomes for all study participants were 
described using frequencies and percentages. All primary analyses were conducted on a 
modified intention-to-treat basis and included participants who completed the trial with an 
observed endpoint, irrespective of compliance to protocol. These analyses excluded all 
pregnancies that ended in a fetal loss (abortions, fetal demise, still births, miscarriages), 
66 
 
congenital anomalies or multiple births. Growth potentials for fetuses with congenital 
anomalies or those from multiple gestation may not be comparable to singleton pregnancies 
without abnormalities. Twenty-six cases (n=26) were excluded, therefore leaving the total 
participants eligible to be included in the analyses as 319.  For the brain growth velocity 
analysis, data were available for only 258 (80.9%) subjects who had at least one measurement 
of HC in-utero.  For the cumulative growth analyses, data were obtainable for 215 subjects 
(67.4%) who had endpoint data on HC recorded at birth.  
 Since there were four repeated measures of cotinine level from participants during the 
trial, the decision was made to identify the unique paths of cotinine levels throughout the 
pregnancy. Group-based latent class trajectory model, a semiparametric method, used to 
discover patterns, was utilized. This approach offers a data-driven method to identify distinct 
individual patterns of a variable of interest and the corresponding probability of falling into 
each pattern, also known as the posterior probability.86 Trajectory analyses were conducted, 
and participants were then classified into groups based on their highest posterior probability.  
The fit of five models, with two to six subgroups, were compared by applying all linear 
terms and quadratic terms (Table A2.5 in Appendices).  Model 4 had the highest Bayesian 
information criterion (BIC), but the log Bayes factor approximation (2(∆BIC)) comparing the 
three-group model to the four-group model was low (4.4 and 3.8 for linear and quadratic terms 
respectively). According to the criteria for the log Bayes factor approximation, 87 there is no 
strong evidence against the null three-group model when comparing the two models, so the 
three-group model has a better fit. Therefore, it appears that three groups is the optimal 
number of latent cotinine subgroups. We also determined the polynomial degree for each 
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trajectory in the three-group model by investigating every permutation of both linear and 
quadratic terms (Table A2.6 in Appendices). We sorted from the best to worst model, based on 
BIC. Consequently, model one was chosen as the best combination of polynomial degrees for 
the three-group cotinine model. The discriminated cotinine group identified was included in our 
analyses as a group variable representing cotinine trajectory. All statistical tests were two-sided 
with an alpha level set at p<0.05 and conducted in SAS 9.4.  
 
Fetal Brain Growth Trajectory  
The primary outcome was the rate of intra-uterine growth rate in HC from the beginning 
of the second trimester of pregnancy until delivery. The two-level linear growth model, a type 
of multilevel modeling, was used for assessing treatment effect and factors that predict 
intrauterine growth in head circumference over time. Multilevel modeling is an analytic 
procedure developed to account for the dependency in observations when data have a nested, 
multilevel structure, such as days (Level 1) nested within-person (Level 2). In this study, the 
Level 1 relationship between gestational age and fetal HC was modeled individually for each 
participant, and the average relationship, across participants, was reported. Level 2 variables 
were then sequentially included in the model to account for differences between babies in the 
average fetal brain growth. These subject level covariates comprised maternal BMI, cotinine 
levels, and fetal gender. Treatment, the primary exposure, was also included. The level 1 
variable, repeated measures of gestational age was centered because it does not have a 
meaningful value of zero (i.e., at a gestational age of zero, fetal brain size or head 
circumference cannot be measured). This variable was centered at 13 weeks because this 
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period signifies the beginning of the second trimester of gestation. Furthermore, no ultrasound 
measurements of HC were recorded before 13 weeks’ gestation. None of the Level 2 variables 
were centered because they had a meaningful value at zero. 
Growth velocity curves (growth trajectories) were plotted and compared between 
mothers on higher-strength folic acid versus those on the standard of care. The treatment 
effect, which is the difference between the two groups, were determined from the multilevel 
models. In the first model, the unconditional growth of HC was modeled as a function of 
gestational age. The intercept and slopes were fit as random effects, which varied across 
fetuses. Estimation methods were assessed in this model using the unstructured, compound 
symmetry, autoregressive (AR (1)), autoregressive heterogeneous and the VC forms of 
covariance matrices. Since the same fixed effects were included in all models, a log-likelihood 
ratio test was used to compare models. Table A2.9 in Appendices shows the comparisons 
between these models. The model with an unstructured covariance matrix had the best fit and 
was utilized in modeling.  
Variables that were either associated with folate treatment or head circumference at 
birth in our bivariate analysis or the literature were included in the model building process. 
Based on the log-likelihood ratio, only three of the likely confounding variables improved the 
model fit namely cotinine group, gender and BMI.  In addition to the unconditional model 
(model 1), results from the following models were also reported: 2) model 1+ treatment; 3) 
model 2 + cotinine group trajectory; 3) model 3 + fetal gender; and 5) model 4 + maternal BMI. 
Model 5 had the best fit. Thus, treatment effect and other fixed and random effects parameter 
estimates were reported from this model.  
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Cumulative Growth in Fetal Brain 
These analyses examined the effect of the intervention on head circumference at birth, 
fetal brain weight, and fetal brain-to-body ratios (BBR). These endpoints which are based on 
data collected at delivery were treated as continuous variables. Since these indices had 
approximately normal distributions (Table A2.10, Fig A2.2-2.4 in Appendices). Independent t-
tests and ANOVA were used to compare the mean values of outcomes between the trial 
treatment groups and participants’ characteristics. Multiple linear regression analyses were 
conducted separately for all the outcomes. To account for potential confounders, we controlled 
for race because of the imbalance across treatment groups after randomization. Cotinine group 
trajectory was also included in the model to account for possible changes in cotinine levels 
during the course of pregnancy. Mean differences in the outcomes and their corresponding 
standard errors were reported. 
 
RESULTS 
 
Study Participants 
Figure 4.1 describes the enrollment and follow-up of the participants. A total of 345 
smoking pregnant women were enrolled in the trial; 171 women were randomly assigned to 
the high-dose folate and 174 to standard dose folate. Of these women, 258 (74.8%) had at least 
one ultrasound measurement of HC and 215 (62.3%) had outcome data on HC at delivery. 
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These numbers, 258 and 215, represent the number of participants included in the modified 
intention-to-treat analysis of brain growth trajectory and cumulative brain growth respectively. 
In Table 4.1, we present the sociodemographic, lifestyle and health-related 
characteristics of study participants by folate dose treatment received. The baseline 
characteristics of the participants in the two groups were well matched with the exception of 
race. Women of ‘other’ race including Hispanic women were more likely to be assigned to the 
standard of care. The average (±SD) age of participants was 26.7 (±5.6) years. The mean 
gestational age at enrollment and the mean baseline folate concentration were 12.3 (±3.9) 
weeks and 718.5 (±187.0) ng/ml respectively. The trial population was predominantly made up 
of women who were single/divorced (90.1%) and without insurance or on public insurance 
plans (95.1%). Approximately two-thirds of the population was either overweight or obese 
(67.7%), and about one-third had hypertension (34.3%) or diabetes (32.7%). 
Table 4.2 shows a description of the overall birth outcomes for all study participants. 
The total number of live births was 312 (90.4%). In all our analyses, we excluded 26 participants 
(7.5%) for the following reasons: pregnancies that ended with induced abortion/miscarriage 
(n=12), congenital anomaly (n=2), fetal demise (n=5), stillborn (n=3), or multiple gestations 
(n=4). There were no distinct differences in the rate of excluded birth outcomes and live births 
by treatment group. 
Figure 4.2 illustrates the longitudinally-derived cotinine trajectories for trial participants. 
We discriminated three distinct groups of maternal cotinine velocities; one with a consistently 
high level of cotinine, another with a low level and the third group with moderate cotinine level 
but a marked decline towards the end of gestation. Approximately 18.9%, 48.3% and 32.8% of 
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the study participants were classified respectively into the groups stated above. At the end of 
the study, only 3.0% of the women with cotinine data at delivery (n=8) had stopped smoking 
(cotinine level of zero). 
 
Fetal Brain Growth Trajectory  
Figure 4.3 displays a spaghetti plot of brain growth for all study participants irrespective 
of their treatment allocation. Overall, a linear trend in growth was observed, with a slight 
reduction in growth rate starting from about 33 weeks of gestational age. Figures A2.5. and 
A2.6 in Appendices show spaghetti plots of brain growth for the high-dose folate and standard-
dose folate groups respectively. In Figure 4.4, we illustrate the fetal brain growth trajectories by 
treatment. There were no noticeable differences between fetal growths in head circumference 
for either treatment group. 
In Table 4.3, we present the results of multilevel linear growth models for the 
longitudinally measured fetal head circumference using the modified intention-to-treat 
population. In the adjusted model, the mean head circumference at 13 weeks (due to centering 
at 13 weeks) for all fetuses was about 109.2mm (P <0.001). This time corresponds to the 
beginning of the second trimester of pregnancy. The average rate of growth in head 
circumference per week starting at the onset of the second trimester of gestation was 9.66mm, 
and this was also statistically significant (P <0.001). Even though infants of individuals who 
received higher strength dose of folate had a 1.18mm larger head circumference than the 
infants of those who received the standard folate, this difference was subtle and not 
statistically significant (P = 0.2762). The between individual variance in the outcome was 
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67.7mm (P <0.001), indicating that the initial head circumference at GA of 13 weeks across 
fetuses was significantly different. This difference was mainly explained by differences in 
maternal BMI status and the gender of the fetus (Table 3). The within-individual variance was 
70.1mm and statistically significant (p<0.001); indicating significant variability in brain growth 
over time across children. Maternal cotinine group level accounted mainly for this difference. 
However, cotinine group trajectory had no significant effect on the rate of brain growth in this 
study. Fetuses who had a smaller HC at the beginning of the second trimester had a significantly 
faster rate of growth than those who had a larger HC (τ10= -6.00). Compared to male fetuses, 
their female counterparts had a 3.2mm slower growth rate in head circumference (P =0.003)  
 
Cumulative Growth in Fetal Brain 
The mean (±SD) head circumference of babies at birth was 33.8cm (±2.0), and there was 
no statistically significant difference by treatment (P =0.1519) (Table 4.4). Differences in head 
circumference were present by cotinine group trajectory, maternal illicit drug use and marital 
status. Married women, mothers in the low cotinine group and those who did not abuse drugs 
while pregnant had babies with significantly larger HC (P ≤0.05). In Table 4.5, we present the 
results from the multivariable linear regression of the effect of treatment on HC at birth. High-
dose folate increased HC at birth by 0.34cm among smokers in pregnancy but this effect was 
not statistically significant (P =0.1844). Compared to mothers with low cotinine levels, mothers 
with moderate or high cotinine levels had babies with approximately 1.2cm lower head 
circumference at birth (P <0.0005). Infants of black mothers had a 0.72cm lower head 
circumference at birth than infants of their white counterparts (P =0.0132).  
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Table 4.6 presents the characteristics of the trial population by mean brain weight and 
brain-body ratios. There were significant differences in the mean brain weight of babies of 
smokers in pregnancy by marital status, illicit drug use and cotinine group (P <0.001). Another 
outcome, the brain-body ratio (BBR), also differed significantly by cotinine group trajectory. In 
this instance, there was an inverse association when compared to HC and brain weight. With 
increasing cotinine group level, BBR increased significantly (P <0.001). BBR also differed 
significantly by treatment group. Mothers who received higher strength folate had lower BBR 
than the mother who received the standard of care (P =0.0043) 
In Table 4.7, the results of the multivariable regression on the effect of treatment on 
fetal brain weight are presented. High-dose folate had no significant effect on brain weight in 
our trial sample of smoking mothers (mean difference 6.90, SE= 5.85, P =0.2396). Compared to 
infants of mothers in the low cotinine groups, infants of mothers in the high or moderate 
cotinine levels had approximately 30g lower brain weight (P <0.001). Infants of black mothers 
also had smaller brain weight at birth than infants of white mothers (P =0.013).  
Fetal brain-body ratio for the infants of the study participants ranged from 7.4%-13.9%. 
Table 4.8 shows the effect of folate treatment on fetal brain-body ratio after controlling for 
potential confounders. The BBR of infants of mothers who received high dose treatment was 
0.33 percentage-point lower than for infants of mothers who received the standard dose of 
folate (P =0.044). Unlike other measures of cumulative brain growth, high cotinine group and 
black race were associated with higher BBR. Compared to women who had low cotinine level, 
mothers with high cotinine levels had 0.93% higher BBR (P <0.001). Infants of black mothers 
had approximately 0.5% higher BBR than infants of white mothers (P =0.0075). 
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DISCUSSION 
This randomized clinical trial compared the efficacy of a combination of higher strength 
folic acid supplementation and enrollment in smoking cessation program versus standard of 
care folic acid dose in conjunction with enrollment in smoking cessation program on increasing 
prenatal brain growth among smokers in pregnancy. Higher strength folic acid supplementation 
in combination with smoking cessation had no effect on intrauterine head growth from the 
beginning of the second trimester of gestation through delivery. We observed a significant 
effect of maternal folic acid treatment on brain-to-body ratio, but no effects on head 
circumference and brain weight at birth. The absence of a difference in the rate of intrauterine 
head growth and head circumference at birth by trial groups might be explained by the 
initiation period of folate supplementation. The mean gestational age at study enrollment and 
commencement of supplementation was 12.3 weeks, approximately the end of the first 
trimester of pregnancy. Previous studies have reported that rapid development of the fetal 
brain occurs during the early stage of gestation, with neurogenesis in most cortical and 
subcortical structures of the brain occurring between 5 and 25 weeks of gestation.118 In the 
current study, a high proportion of the participants were enrolled after the first trimester, thus, 
there is a possibility that we missed the opportunity to demonstrate a treatment effect if it 
indeed exists.  
The infant of women on higher-strength dose experienced a 0.33%-point reduction in 
brain-body ratio compared to their counterparts on the standard treatment (P =0.044). This 
may indicate that folate does not favor fetal brain over fetal body growth, particularly if 
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supplementation is not commenced early in pregnancy when rapid brain growth occurs. A high 
BBR signifies a larger brain weight for a given head circumference, and this is commonly 
observed in small-for-gestational-age infants116 and intrauterine growth restriction (IUGR).120 
Therefore, a decrease in BBR found in this trial correlates with a lower risk of SGA birth among 
the high folate dose group. Harel and colleagues120 reported that higher the brain-body ratio 
was associated with more severe the intrauterine growth restriction (IUGR) process and a 
greater the risk for the fetal brain to be affected.120 The observed reduction in BBR in the 
current might have important consequences for families and the health care systems by 
reducing the burden of caring for individuals associated sub-optimal neurodevelopmental 
problems. Because a relatively large segment of women smoke during pregnancy,3, 33, 34, 119 a 
0.33%-point reduction in brain-to-body ratio will translate to preventing a large number of 
probable cases of infants with neurocognitive and behavioral problems. 
Significant relationships between cotinine trajectory group and the cumulative 
measures of brain growth were also observed. A dose-response relationship was observed for 
all outcomes. Higher cotinine level was associated with worse outcomes i.e. lower HC at birth, 
reduced brain weight and higher BBR. Lindley et al107 found similar effects of smoking on HC 
and BBR. In their observational study, nonsmokers were compared with mothers who stopped 
smoking by 32 weeks of gestation, light smokers who continued to smoke, and heavy smokers 
who continued to smoke during pregnancy. A dose-response gradient was observed with these 
self-reported smoking levels. It is well documented that maternal smoking affects fetal brain 
development and results in neurocognitive issues such as deficits in IQ in the offspring.118, 125 
Because infants born to mothers with lower levels of cotinine had a reduced risk of adverse 
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fetal brain outcome than those born to mothers with higher levels, being able to get women to 
reduce smoking or maintain minimal smoking if not completely quit will have significant 
implication for reducing the incidence of neurodevelopmental problems. It is noteworthy that 
despite being enrolled in smoking cessation programs, only 3% of the study participants quit 
smoking. Other findings in this trial are the increased risk of adverse cumulative brain growth 
outcomes among blacks. Our study confirms previous reports that black mothers compared to 
white mothers have worse birth outcomes including infants with lower birth weight and smaller 
head circumference.89, 98  
There are some limitations to note regarding the present study. We lost a relatively high 
proportion of the participants to follow-up. For instance, in our multilevel modeling, we had 
data on only 82.7% (n= 258) of the 319 women eligible to be included in the modified intention-
to-treat analysis. There were no significant differences in demographic characteristics between 
the participants lost to follow-up and those who remained in the study. Therefore, we do not 
expect loss to follow-up to bias our result in a significant way. We did not directly assess or 
control for the effect of diet, a possible confounder in this study. However, there is a reduced 
likelihood in dietary differences by treatment groups because of randomization. Furthermore, 
the baseline comparison of RBC folate, a proxy for long-term folate diet supports this claim. As 
with most clinical trials, the generalizability of our findings to an external population is an issue. 
Voluntary participants in studies are usually different from nonparticipants. In this instance, the 
participants may be more health conscious and, therefore, our findings could be biased towards 
the null. In the baseline assessment of RBC folate in this study, it was observed that only 2 
women had folate deficiency as defined by the laboratory’s guideline of less than 280 ng/ml.  
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The study sample was made up of low income women with a high proportion of minority, 
further limiting the generalizability of the findings. 
There are numerous strengths of this trial. The use of double-blind, randomized clinical 
trial allows for causal inference. We conducted modified intention-to-treat analysis, so our 
findings will closely represent the effectiveness of higher strength folic acid in improving 
prenatal brain growth under real-world conditions. To our knowledge, this is the first 
randomized control trial to report on the efficacy of high strength folic acid in combination with 
enrollment in smoking cessation program in preventing adverse fetal brain outcomes among 
smokers in pregnancy. 
The vulnerability of the developing fetal brain is dependent on whether an exposure or 
its active metabolite(s) reaches the developing nervous system and the period of exposure.118 In 
our trial, we cannot say with certainty that folate supplementation was commenced at the 
critical period of brain growth and that folate reached the brain at the dose at which we 
supplemented. Future experimental studies should investigate the role of early folic acid 
supplementation among smokers starting from before conception until delivery. This method 
may help in identification of the critical period of development associated with maximum 
folate-associated brain growth. It is also crucial to understand the differences between the 
effects of folic acid supplementation versus blood folate concentrations on fetal brain. Blood 
folate levels including RBC and serum folate are better proxies for the assessment of folate 
status.122 These biomarkers are recommended for assessing folate bioavailability for optimal 
neural cells growth and development.  
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In conclusion, we demonstrated a substantial reduction in brain-to-body-ratio with the 
use of higher strength folate initiated during early-mid pregnancy. However, no treatment 
effects were found on intrauterine brain growth rate, HC at birth and brain weight. The 
significant findings show that smokers in pregnancy may benefit from folate supplementation 
in reducing the risk of having infants with impaired brain-body proportionality. A decrease in 
the proportion of infants with impaired BBR might contribute to a reduction in morbidity and 
health care cost associated with future neurocognitive disorders. 
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Figure 4.1. Enrollment, randomization, and follow-up of participants 
 
345 women underwent randomization 
Baseline: 171 were 
assigned to receive 4mg 
of folic acid once daily 
Baseline: 174 were 
assigned to receive 
0.8mg of folic acid once 
daily 
Visit 2: 149 participants 
attended follow-up visit 
 
Visit 2: 145 participants 
attended follow-up visit 
Visit 3: 145 participants 
attended follow-up visit 
Visit 3: 137 participants 
attended follow-up visit 
 
19 Lost to follow-up  
7 Fetal loss  
 
110 Completed study with outcome data 
on head circumference and were 
included in the modified intention-to-
treat analysis of cumulative growth 
 
105 Completed study with outcome data 
on head circumference and were 
included in the modified intention-to-
treat analysis of cumulative growth 
 
 
8 Lost to follow-up 4 Lost to follow- up 
13 Lost to follow-up 
or delivered outside 
of center, 2 Fetal 
loss, 1 Congenital 
anomaly, 2 Multiple 
gestation 
11 Lost to follow-up 
or delivered outside 
of center, 4 Fetal 
loss, 1 Congenital 
anomaly, 2 Multiple 
gestation 
18 Lost to follow 
7 Fetal loss 
 
128 Were included in the 
modified intention-to-treat 
analysis of brain growth 
trajectory (at least one 
intrauterine measure of HC) 
  
130 Were included in the 
modified intention-to-treat 
analysis of brain growth 
trajectory (at least one 
intrauterine measure of HC) 
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Table 4.1. Baseline socio-demographic, lifestyle and health-related characteristics of all 
randomized study participants by folate treatment (N=345). 
Variables   High-Dose 
Folate (N=171) 
Standard Dose 
Folate (N=174) 
P-valueb 
 Na (%) Count (%) Count (%)  
Age in years  26.7±5.6 26.4±5.1 27.3±5.8 0.1035 
Gestational Age  12.3±3.9 12.4±3.9 12.2±3.9 0.5721 
Baseline Cotinine  2.9±1.4 3.0±1.5 2.9±1.4 0.3535 
Baseline Folate 718.5±187.0 731.3±180.9 706.0±192.3 0.2100 
Race       0.0274 
         White 148 (42.9) 78 (45.6) 70 (40.2)  
         Black         140 (40.6) 74 (43.3) 66 (37.9)  
         Other 47 (16.5) 19 (11.4) 38 (21.8)  
Marital Status       0.255 
          Married   34 (9.8) 20 (11.7) 14 (8.05)  
          Single/ Divorced 311 (90.1) 151 (88.3) 160 (91.9)  
Spanish Speaking        
         Yes 21 (6.1) 8 (4.7) 13 (7.5) 0.2780 
         No 324 (93.9) 163 (95.3) 161 (92.5)  
Insurance       0.4336 
         Public/None 328 (95.1) 161 (94.1) 167 (96.0)  
         Private 17 (4.9) 10 (5.9) 7 (4.0)  
 BMI        
         Not overweight 111 (32.4) 53 (31.0) 58 (33.7) 0.1239 
         Overweight 85 (24.8) 36 (21.0) 49 (28.5)  
         Obese 147 (42.9) 82 (47.9) 65 (37.7)  
Alcohol Use        
        Yes 30 (9.5) 18 (11.2) 12 (7.6) 0.2727 
         No 287 (90.5) 142 (88.7) 145 (92.4)  
Illicit Drug Use        
         Yes 94 (31.0) 50 (32.9) 44 (29.1) 0.4798 
          No 209 (69.0) 102 (67.1) 107 (70.9)  
Stress Score        
         High 191 (55.4) 95 (55.6) 96 (55.2) 0.9498 
          Low 154 (44.6) 76 (44.4) 78 (44.8)  
Depression Score        
         High 63 (18.3) 31 (18.1) 32 (18.4) 0.9498 
         Low 282 (81.7) 140 (81.9) 142 (81.6)  
Hypertension        
        Yes 113 (34.3) 54 (33.1) 59 (35.5) 0.6449 
         No 216 (65.7) 109 (66.9) 107 (64.5)  
Continued on next page 
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Table 4.1. (Continued) 
Diabetes        
         Yes 108 (32.7) 52 (31.9) 56 (33.5) 0.7522 
         No 222 (67.3) 111 (68.1) 111 (66.5)  
Heart Disease        
         Yes 42 (12.8) 22 (13.5) 20 (12.1) 0.7093 
         No 286 (87.2) 141 (86.5) 145 (87.9)  
*Plus-minus values are means ±SD. a. some cell numbers do not sum up to 345 due to missing data. b significant p 
values are in bold. 
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Table 4.2. Birth Outcomes for Study Participants in the Intention-to-Treat Population (N=345) 
Event High-Dose Folate (N= 
171) 
Standard Dose Folate (N= 
174) 
Pvalue 
                                                no. of participants (%)  
Live birth 152 (88.9) 160 (91.9) 0.0798 
Induced 
abortion/miscarriage 
6 (3.5) 6 (3.4) 0.4272 
Congenital anomaly 1 (0.6) 1 (0.6) 0.9755 
Fetal demise 3(1.7) 2 (1.1) 1.0000 
Still born 2 (1.2) 1 (0.6) 0.6830 
Multiple gestation 2 (1.2) 2 (1.1) 0.6206  
 
*Complete loss to follow-up 5 (2.9) 2 (1.1) 1.0000 
*Indicates delivery records that were not available or retrievable. 
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Figure 4.2. Longitudinal-Derived Cotinine Trajectories in the Modified Intention-to-Treat 
Population (n=319) 
Each straight line reflects an individual cotinine trajectory: 1-low level; 2-moderate level; and 3-
high level. 
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Figure 4.3. Individual Growth Velocity Trajectories in Fetal Head Circumference from the 
Beginning of Second Trimester till Delivery (N=258) 
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Figure 4.4. Trajectories in Head Circumference of Fetuses of Participants by Treatment from 
the Beginning of Second Trimester till Delivery (N=258) 
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Table 4.3. Multilevel linear growth models for the effect of treatment on growth in fetal head 
circumference (N=258) 
Parameter Estimate 
 Model 1 Model 2 Model 3 Model 4 Model 5 
Fixed effects      
Intercept (γ00) 108.16 107.72 107.67 108.19 109.20 
GA a (γ01) 9.70 9.70 
 
9.70 9.69 9.66 
Treatment (γ10)      
        High Dose  1.02 0.98 1.38 1.18 
        Standard Dose  - - - - 
Group      
     Low   0.94 0.90 0.78 
     Moderate   1.30 1.73 1.84 
     High   -   
Gender      
    Female    -3.10 -3.21 
    Male      
BMI      
   Not Overweight     -1.61 
   Overweight     -0.75 
   Obese      
Deviance (-2LL) 8188.6 8185.7 8180.4 7775.2 7736.6 
Note. a Centered variable (centering done using the value 13 weeks); b Cotinine at delivery. Estimates in bold are 
significant at p-value <0.05. C Model 1 was used as baseline model for computing the explained individual variance 
(σ2) in head circumference growth accounted for by folate treatment d Model 1 was used as baseline model for 
computing the explained intercept variance (τ00) in head circumference growth accounted for by folate treatment.  
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Table 4.4. Maternal and fetal characteristics of the study sample by mean head circumference 
at birth (N = 215) 
Variables Mean (SD) p-value 
Overall 33.8 (2.0)  
Treatment  0.1519 
   High-dose 34.0 (1.5)  
   Low-dose 33.6 (2.3)  
Maternal Age  0.9197 
     18–24 33.7 (1.7)  
     25–34 33.7 (2.1)  
     ≥35 33.9 (2.2)  
Maternal Race  0.3983 
    Non-Hispanic white 34.0 (1.6)  
    Non-Hispanic black 33.5 (1.9)  
    Other 33.6 (3.0)  
Marital status  0.0500 
     Married 34.5 (1.7)  
     Unmarried 33.7 (2.0)  
Insurance Type  0.2550 
    Private 34.2 (1.2)  
     Public /Uninsured 33.7 (2.0)  
Trimester   0.9417 
     First  33.8 (2.2)  
     Second  33.9 (1.7)  
Body mass index  0.0723 
     <25 33.4 (2.1)  
     25–30 33.7 (2.0)  
     >30 34.0 (1.8)  
Cotinine group  0.0004 
      Low 34.4 (1.4)  
      Moderate 33.3 (2.3)  
      High 33.3 (2.1)  
Depression Score  0.1187 
     <12 33.9 (1.9)  
     ≥12 33.3 (2.1)  
Perceived Stress Score  0.8070 
    Low 33.7 (1.8)  
    High 33.8 (2.1)  
Continued on next page 
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Table 4.4. (Continued) 
Alcohol Use  0.2156 
        Yes 33.9 (3.0)  
         No 33.9 (1.7)  
Illicit Drug Use  <0.0001 
         Yes 33.0 (2.2)  
           No 34.3 (1.5)  
Hypertension  0.1254 
        Yes 33.6 (1.7)  
         No 33.9 (2.0)  
Diabetes  0.3835 
         Yes 33.7 (2.1)  
         No 33.8 (1.8)  
Heart Disease  0.5576 
         Yes 33.4 (2.3)  
         No 33.8 (1.8)  
Gender of child  0.2066 
   Female 33.7 (1.6)  
    Male 34.1 (2.1)  
Trimester=trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group. 
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Table 4.5. Effect of folate treatment on fetal head circumference (cm) at birth (n=215) 
Variables β  SE p-value 
Intercept 34.29 0.48 <0.0001 
Treatment   0.3447 
      High dose 0.34 0.26 0.1844 
      Low dose ref -  
Cotinine group    
       Low ref -  
       Moderate  -1.16 0.29 <0.0001 
       High -1.31 0.36 0.0004 
Race    
       White ref -  
       Black -0.72 0.29 0.0132 
       Other -0.51 0.40 0.2038 
*Adjusted for cotinine group trajectory and race. β= Estimate; SE= Standard error; ref= Reference group. 
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Table 4.6. Maternal and fetal characteristics of the study sample by brain weight and brain-
body ratio (n = 215) 
 Brain Weight Brain-Body Ratio 
Variables Mean (SD) p-value Mean (SD) p-value 
Overall 316.1 (44.4)  10.4 (1.2)  
Treatment  0.2167  0.0043 
   High dose 320.0 (36.4)  10.3 (1.1)  
   Low dose 312.5 (50.8)  10.6 (1.3)  
Maternal Age  0.8748   
     18–24 314.9 (37.5)  10.2 (1.2) 0.1287 
     25–34 316.0 (47.3)  10.5 (1.2)  
     ≥35 320.1 (51.8)  10.8 (1.4)  
Maternal Race  0.3265  0.1844 
    Non-Hispanic white 320.6 (38.0)  10.3 (1.3)  
    Non-Hispanic black 310.8 (42.8)  10.6 (1.2)  
    Other 315.6 (64.7)  10.5 (1.2)  
Marital status  0.0396  0.1580 
     Married 334.1 (41.5)  10.2 (0.9)  
     Unmarried 314.0 (44.4)  10.5 (1.3)  
Insurance Type  0.4729  0.3365 
    Private 324.1 (30.3)  10.7 (1.2)  
    Public /Uninsured 315.5 (45.3)  10.4 (1.2)  
Trimester   0.9450  0.4609 
     First  316.3 (47.4)  10.5 (1.2)  
     Second  315.9 (41.2)  10.4 (1.3)  
Body mass index  0.0613  0.0718 
     <25 307.1 (44.8)  10.7 (1.3)  
     25–30 315.7 (45.2)  10.3 (1.2)  
     >30 323.9 (42.9)  10.3 (1.2)  
Cotinine group  0.0004  0.0030 
     Low 329.5 (35.0)  10.2 (1.2)  
     Moderate 306.0 (50.2)  10.4 (1.2)  
      High 305.0 (44.4)  11.0 (1.2)  
Depression Score  0.1091  0.0863 
     <12 318.4 (43.9)  10.4 (1.2)  
     ≥12 305.6 (45.8)  10.7 (1.4)  
Perceived Stress Score  0.7081  0.0725 
    Low 315.0 (41.1)  10.3 (1.2)  
    High 317.2 (47.5)  10.6 (1.2)  
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Table 4.6. (Continued) 
Alcohol Use  0.2348  0.4266 
       Yes 298.4 (66.0)  10.3 (1.2)  
       No 319.9 (40.3)  10.6 (1.4)  
Illicit Drug Use  <0.0001  0.3410 
        Yes 299.5 (47.4)  10.3 (1.1)  
        No 327.1 (37.8)  10.5 (1.4)  
Hypertension  0.1038  0.0851 
        Yes 324.0 (44.5)  10.2 (1.2)  
        No 313.0 (41.9)  10.6 (1.1)  
Diabetes  0.3830  0.2398 
        Yes 321.3 (39.0)  10.3 (1.2)  
        No 315.6 (43.7)  10.5 (1.2)  
Heart Disease  0.6253  0.3607 
        Yes 313.0 (50.8)  10.3 (1.2)  
        No 317.5 (42.2)  10.5 (1.3)  
Gender of child  0.1300  0.6333 
      Female 313.9 (38.7)  10.3 (1.2)  
     Male 323.4 (48.1)  10.4 (1.2)  
Trimester=Trimester at study enrollment and data collection; Cotinine group=cotinine trajectory group 
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Table 4.7. Effect of folate treatment on fetal brain weight (g) at birth (n=215) 
Variables β  SE p-value 
Intercept 328.55 10.74 <0.0001 
Treatment   0.2396 
      High dose 6.90 5.85  
      Standard dose ref - - 
Cotinine group    
       Low ref -  
       Moderate  -25.81 6.54 <0.001 
       High -29.56 8.20 0.0004 
Race    
       White ref -  
       Black -16.16 6.48 0.0134 
       Other -8.79 9.00 0.3296 
*Adjusted for race and cotinine group trajectory. β= Estimate; SE= Standard error; ref= Reference group. 
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Table 4.8. Effect of folate treatment on fetal brain-body ratios at birth (n=215) 
 
Variables β  SE p-value 
Intercept 10.44 0.30 <0.0001 
Treatment   0.0436 
      High dose -0.33 0.16  
      Low dose ref - - 
Cotinine group    
       Low ref -  
       Moderate  0.21 0.18 0.2506 
       High 0.94 0.23 <0.0001 
Race    
       White ref -  
       Black 0.49 0.18 0.0075 
       Other 0.30 0.25 0.2319 
*Adjusted for race and cotinine group trajectory. β= Estimate; SE= Standard error; ref= Reference group. 
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CHAPTER FIVE: 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
This research has two main sections: (1) the cross-sectional study; and (2) the 
randomized clinical trial. The findings of the cross-sectional study suggest that smokers may 
have a slightly lower but insignificant red blood cell (RBC) folate than non-smokers and that a 
negative correlation exists between salivary cotinine levels and RBC folate concentrations. In 
the RCT conducted among smokers in pregnancy, we found that 4mg/day dose of higher-
strength folic acid in combination with enrollment in a smoking cessation program had a 
significant effect on birth weight, brain-body-ratio (BBR) and a trend towards significance for 
the risk of small-for-gestational-age (SGA). However, higher-strength folic acid demonstrated 
no effects on the rate of intrauterine brain growth, and head circumference and brain weight at 
birth. A consistent finding across fetal body size outcomes was the dose-response effect of 
cotinine trajectory groups. Of importance is that only 3% of the study population quit smoking 
by the end of the trial, despite being enrolled in smoking cessation program and committing to 
quit smoking. 
The statistically significant inverse relationship between salivary cotinine levels and RBC 
folate concentrations may provide evidence in support of impaired folate metabolism among 
smokers and the need to increase folate supplementation among this high-risk group. The 
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observed significant effect of high dose folate on birthweight, brain-to-body ratios, and a 
modest protective effect on SGA are of clinical and public health relevance. These indices are 
known to be connected to poor short-term and long-term health outcomes, and infant 
mortality. Thus, a 140g increase in birthweight, a 0.33%-point reduction in impaired BBR and a 
31% decrease in the incidence of SGA birth, as observed in this trial, would translate into lower 
infant morbidity and mortality, and a reduction in health care expenditures. Infants with SGA 
and higher BBBR are more likely to have neurocognitive problems.123 A reduction in SGA births 
and children with impaired BBR could considerably impact the number of individuals who 
would require services such as special educational resources and social support due to 
neurocognitive and behavioral problems. 
Smoking cessation is a well-established, effective preventive measure to improve birth 
outcomes but it is not particularly useful in low-income mothers as observed in this trial. Thus, 
there is a need to investigate smoking interventions that are tailored and developed specifically 
for this sub-group and identify ways to improve birth outcomes for smokers in pregnancy. 
Higher-strength folic acid supplementation seems like an effective, safe and cheap option. 
Practically, the health care provider may be able to prescribe this affordable supplement to at-
risk low-income mothers and increase their likelihood of having infants with higher birth weight 
and appropriate-for-gestational-age babies. Infants born to mothers with lower levels of 
cotinine had a reduced risk of adverse fetal brain and body size outcome than those born to 
mothers with higher levels of cotinine. Getting women to reduce smoking or maintain minimal 
smoking, if they cannot completely quit, will have significant implications for decreasing the 
incidence of adverse birth outcomes and future health problems. Being able to increase birth 
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weight and reduce SGA births in these disadvantaged group of women may contribute 
significantly to decreasing infant health disparities in the United States. This aligns with the 
Healthy People 2020 goals of reducing the rate of fetal and infant deaths [(Maternal, Infant and 
Child Health, Objective 1 (MICH-1)].124 
 
Further Research Needed 
Higher strength folic acid supplementation may have the potential to offer smokers in 
pregnancy a safe, comfortable and convenient option to reduce their risk of adverse birth 
outcomes. Additionally, the possibility of a decrease in SGA births by approximately 31% would 
be huge considering the number of cases of SGA births that can be prevented, and the 
subsequent reduction of burden on families and the health care system. Higher strength folic 
acid supplementation in pregnant women who smoke might be a cost-effective way to reduce 
low birth weight and SGA associated infant morbidity and mortality. Future studies with larger 
sample sizes and diverse populations are indicated to confirm or refute the results of this study. 
Of importance are those results that showed a trend towards statistical significance; they are 
worthy of further investigation to determine true associations. Additionally, future research 
should investigate the effect of potential modifiers, such as cotinine trajectory group on the 
association between higher strength folate supplementation and birth outcomes. Observational 
studies have demonstrated a significant reduction in SGA risk, only if folic acid supplementation 
is commenced before conception.  Randomized controlled trials with startup during the 
preconception period and follow-up until delivery are warranted to identify the most folate-
sensitive period of fetal growth. These studies should aim to determine the optimal dose of 
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folic acid supplement, and compare the effects of folate assessed via biomarker test vs. self-
reported supplementation on birth outcomes. 
In conclusion, the findings from this study contribute to the body of evidence regarding 
the effect of maternal folic acid supplementation on fetal brain and body size among low-
income mothers who smoke during pregnancy. It is the first RCT to investigate the efficacy of 
folic acid in improving adverse birth outcomes among smokers. The folate-dependent pathway 
is one of the many plausible mechanisms that link tobacco use in pregnancy to adverse birth 
outcomes. We hope that this study will stimulate further multi-pathway research in mitigating 
the effects of prenatal smoking on adverse birth outcomes.  
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APPENDIX 1. REVIEW OF THE LITERATURE 
 
A1.1. PERINATAL SMOKING 
Harmful health behavior such as smoking is prevalent during the periconceptional 
period among women.  About 21% of women of reproductive age smoke and approximately 10-
14% of women continue to smoke during pregnancy1-4 in spite of substantial evidence of its 
deleterious health effects. Not only is the rate of smoking high among women, about one-third 
of women of reproductive age are also exposed to environmental tobacco smoke i.e. second-
hand exposure.5 
Smoking during pregnancy remains one of the most preventable and highly prevalent 
causes of infant morbidity and mortality. In the United States, it accounts for over 1000 
perinatal deaths each year6 and is a significant cause of a range of adverse pregnancy outcomes 
including intrauterine growth restriction, miscarriage, preterm birth, Sudden Infant Death 
Syndrome (SIDS) and placental abruption.7-9 Prenatal smoking is also associated with long-term 
consequences of neurodevelopment disorders and impaired cognitive function in the 
offspring,10 attention deficit disorders,11,12 behavioral problems, 13,14 and antisocial 
behavior.15,16 
Public health initiatives have helped reduce the prevalence of smoking in pregnancy 
over the past few decades, but disparities still exist with lower rates of decline among women 
of lower socioeconomic status.9 Women who continue to smoke during pregnancy usually have 
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a low income, limited education, high parity, are without a partner, have low levels of social 
support, and receive publicly funded maternity care.9,17-19 
  
A1.2. FOLATE  
Folate or vitamin B9 is one of the 13 essential vitamins. It cannot be synthesized de 
novo by the body and must be obtained either from food intake or dietary supplementation.20 
Dietary folate is a naturally occurring nutrient which can be consumed through food sources 
such as leafy green vegetables, egg yolk, liver, legumes, and citrus fruit. The synthetic dietary 
supplement form of folate that is present in artificially enriched foods and pharmaceutical 
vitamins is called folic acid. Folic acid (pteroylglutamic acid) is used to denote the fully oxidized 
chemical compound, not present in natural foods while ‘folate’ is a more encompassing term 
that is used to indicate the large group of compounds possessing the same vitamin activity.21 
Adequate folate intake, particularly in pregnancy is required for cell division and 
homeostasis due to the vital role of folate coenzymes in nucleic acid synthesis, methionine 
regeneration, and in the oxidation, and reduction of one-carbon units required for normal 
metabolism.22 The supply of folate coenzymes in the body depends primarily on the quantity 
and bioavailability of ingested folate and the rate of excretion in the urine and feces through 
catabolism. In pregnancy, the demands for folate increase because it is required for fetal 
growth and development.20,23 Folate deficiency has been associated with health problems in 
mothers (such as anemia, peripheral neuropathy) and their babies (such as preterm birth and 
congenital abnormalities).20 
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Several studies including a recent systematic review of randomized or quasi-randomized 
trials evaluating the effect of periconceptional folate supplementation in preventing neural 
tube defects24-28 showed a protective effect of daily folic acid supplementation (alone or in 
combination with other vitamins and minerals) on neural tube defect (NTDs). Based on the 
consistent evidence about the protective effect of folic acid supplementation against NTDs, the 
United States Public Health Service recommended daily supplementation with 400μg (0.4mg) of 
folic acid for all women of reproductive age.29 Despite the known advantages of folate, many 
women still do not follow the recommendations, and this is particularly true for women from 
low socioeconomic backgrounds.30,31 Additionally, study on trends in red blood cell (RBC) folate 
demonstrates disparity by race.32 Certain race groups including non-Hispanic black women are 
yet to meet the 2010 national health objective of increasing the median RBC folate level among 
women of reproductive age to 220 ng/mL RBC.32 
 
A1.3. SMOKING AND FOLATE 
The negative association between smoking, and folic acid intake and metabolism is well 
documented in the literature.33-36 Smokers are less likely to consume quality diet including 
adequate folate37and have increased oxidative catabolism and altered absorption of serum 
folate.38 Research has shown that smokers have lower serum folate levels than nonsmokers.39-
41 Tobacco smoke exposures in pregnancy may increase disease risk among children by 
reducing folate bioavailability during the critical period of fetal development. 36, 42-45 
Since there is evidence to support lower serum folate among smokers, folic acid 
supplementation during pregnancy may be relevant to smokers and in higher dose than in non-
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smokers.  This is because of its importance in DNA synthesis and repair from damages due to 
smoking coupled with increased folate demand in pregnancy.33,46,47 The process of DNA 
methylation is dependent on the presence of methyl donors (provided by nutrients such as folic 
acid, methionine, and choline) and methyltransferases. As folate is an important substrate in 
methylation reactions, the demand for folate may be higher in smokers than in non-smokers, 
thereby depleting folate stores.  Because of the depleting folate stores during pregnancy, there 
is a decline in the major methyl donor, S-adenosyl methionine (SAM) which is required for DNA 
methylation48; a process required for optimal fetal growth.49, 50 
 
A1.4. PRENATAL SMOKING AND FETAL BODY AND BRAIN SIZE 
Maternal smoking can cause several adverse health outcomes across the lifespan. 
However, in comparison to adults, the developing fetus may be particularly sensitive to the 
harmful effects of smoking because of reduced nicotine detoxification capability.51, 52 Birth 
weight is the most important predictor of infant health and survival. The effect of prenatal 
smoking on increased risk of low birth weight (LBW) and intrauterine growth restriction is well 
documented.53-57 Tobacco exposure during pregnancy is associated with impaired fetal growth 
from early pregnancy onwards and increases the risks of neonatal and future health 
complications.55,58,59 
Numerous studies have also observed reduced fetal head circumference and biparietal 
diameter in fetuses of smoking mothers and have described these parameters of general 
symmetrical intrauterine growth restriction.55,60-63 Jaddoe et al55 found that continued maternal 
smoking in pregnancy led to a reduction in the growth of head circumference by about 0.56 
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mm/week, and the degree of growth restriction was found to be dose-dependent on smoking 
levels. Unlike in animal studies where nicotine has been shown to directly inﬂuence fetal brain 
development (the use of animal models permits a direct assessment of causality),64 an indirect 
pathway has been suggested in humans. This evidence is based on studies that indicate that the 
relationship between perinatal smoking and behavioral/cognitive development in the offspring 
may be mediated by brain deﬁcits or reduced fetal head size.65 
 
A1.5. FOLIC ACID AND FETAL BODY AND BRAIN SIZE 
During pregnancy, folate requirements are 5- to 10-fold higher than in non-pregnant 
women to cover the needs of fetal growth and development.66 Low folate intake and low RBC 
folate level in the late pregnancy increase the risk of SGA birth.40,67,68 Several studies suggest a 
possible benefit of maternal folate consumption or high serum/RBC folate level on birth weight. 
40,67-70 In a review of randomized clinical trials (RCTs) investigating the effect of folic acid 
supplementation on birth weight, a significant dose-response association between folate intake 
and birth weight was observed.70  
The role of folate in brain growth has also been established, and the changes in brain 
structure due to folate deficiency may be long-lasting and contribute to behavioral difficulties 
later in life.71 Conversely, high total folate intake and maternal erythrocytes folate 
concentration in early pregnancy promote growth in the fetal head.72 Results from the Schlotz  
et al72 longitudinal study of a birth cohort also show inverse associations between maternal 
folate status in early pregnancy with behavioral problems (hyperactivity/inattention and peer 
problems) in childhood. These associations were found to be mediated by fetal head 
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circumference at birth. Head circumference correlates closely with fetal brain volume73 and is 
used as a proxy for assessing brain growth.74 
Some biologically plausible hypotheses have been used to explain the associations 
between maternal folate status and fetal size such as a reduction in concentration and activity 
of maternal folic, and reduced placental blood flow (Figure A1.1) Folate has many roles in cell 
function and gene expression, through the process of DNA methylation.75 Low folate level is 
associated with elevated total homocysteine (tHcy). The high serum levels of this amino acid 
have been associated with several clinical conditions, including placental vasculopathy,76,77 
which is well known to affect fetal growth.78 Fetal growth may be influenced directly by 
elevated tHcy or through other effects of reduced folate such as modulation of gene expression 
through altered DNA methylation.79 
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Figure A1.1. Pathways through which smoking could lead to adverse birth outcomes 
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APPENDIX 2. SUPPLEMENT TABLES AND FIGURES 
 
Table A2.1. Baseline characteristics of the study sample by mean blood folate concentrations  
Variables Erythrocyte Folate, ng/mL 
 Median (25th, 75th percentile) P-value 
Overall 718.0 (577.0, 860.0)  
Maternal Age  0.384 
     18–24 704.0 (569.0, 835.0)  
     25–34 718.0 (579.0, 853.0)  
     ≥35 763.0 (542.0, 917.0)  
Maternal Race  0.613 
    Non-Hispanic white 730.0 (580.0, 874.0)  
    Non-Hispanic black 705.0 (567.0, 842.0)  
    Other 727.0 (579.0, 838.0)  
Marital status  0.939 
     Married 712.0 (585.0, 876.0)  
     Unmarried 716.5 (571.5, 858.0)  
Insurance Type  0.632 
    Private 711.0 (583.0, 811.0)  
     Public /Uninsured 716.0 (573.0, 865.0)  
Trimester at enrollment  <0.001 
     First  655.5 (533.0, 801.0)  
     Second  788.0 (654.0, 935.0)  
Body mass index  0.023 
     <25 690.5 (558.5, 801.5)  
     25–30 697.5 (579.0, 855.0)  
     >30 752.0 (582.0, 895.0)  
Depression Score  0.386 
     <12 712.0 (569.0, 851.0)  
     ≥12 724.0 (580.0, 910.0)  
Perceived Stress Score  0.262 
    Low 706.0 (560.0,864.0)  
    High 741.0 (592.0, 857.0)  
Smoke Tobacco  0.835 
     Yes 716.5 (577.5, 859.5)  
     No 712.0 (567.0, 865.0)  
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Table A2.2. Spearman correlation coefficients for folate level and continuous covariates 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
Number of Observations 
  Folate Age GA in weeks EPDS PSS 
Folate Level 
Folate 
 
1.00000 
  
495 
 
0.06558 
0.1451 
495 
 
0.27895 
<.0001 
495 
 
0.04066 
0.3681 
492 
 
0.03075 
0.4971 
490 
 
Maternal Age 
Age 
 
0.06558 
0.1451 
495 
 
1.00000 
  
496 
 
0.07127 
0.1129 
496 
 
0.00084 
0.9851 
493 
 
-0.03127 
0.4894 
491 
 
Gestational Age 
GA in weeks 
 
0.27895 
<.0001 
495 
 
0.07127 
0.1129 
496 
 
1.00000 
  
496 
 
0.01334 
0.7676 
493 
 
0.00252 
0.9556 
491 
 
Depression Score 
EPDS 
 
0.04066 
0.3681 
492 
 
0.00084 
0.9851 
493 
 
0.01334 
0.7676 
493 
 
1.00000 
  
493 
 
0.66402 
<.0001 
488 
 
Stress Score 
PSS 
 
0.03075 
0.4971 
490 
 
-0.03127 
0.4894 
491 
 
0.00252 
0.9556 
491 
 
0.66402 
<.0001 
488 
 
1.00000 
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Table A2.3. Spearman correlation coefficients for cotinine level and continuous covariates 
 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
Number of Observations 
  Cotinine Maternal Age GA in weeks EPDS PSS 
Cotinine 
Cotinine 
 
1.00000 
  
495 
 
0.06639 
0.1402 
495 
 
0.08681 
0.0536 
495 
 
0.28958 
<.0001 
492 
 
0.26297 
<.0001 
490 
 
Maternal Age 
Age 
 
0.06639 
0.1402 
495 
 
1.00000 
  
496 
 
0.07127 
0.1129 
496 
 
0.00084 
0.9851 
493 
 
-0.03127 
0.4894 
491 
 
Gestational age 
GA in weeks 
 
0.08681 
0.0536 
495 
 
0.07127 
0.1129 
496 
 
1.00000 
  
496 
 
0.01334 
0.7676 
493 
 
0.00252 
0.9556 
491 
 
Depression Score 
EPDS 
 
0.28958 
<.0001 
492 
 
0.00084 
0.9851 
493 
 
0.01334 
0.7676 
493 
 
1.00000 
  
493 
 
0.66402 
<.0001 
488 
 
Stress Score 
PSS 
 
0.26297 
<.0001 
490 
 
-0.03127 
0.4894 
491 
 
0.00252 
0.9556 
491 
 
0.66402 
<.0001 
488 
 
1.00000 
  
491 
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Table A2.4. Schedule of data collection, instruments and procedures used in the in the study 
 Baseline 
Visit 
Visit 1 Visit 2 Delivery 
Gestational Age (GA) <21 weeks  18-27 
weeks 
28-36 
weeks 
GA at 
Delivery 
American College of 
Obstetrics and Gynecology form (ACOG) 
X    
Edinburgh Perinatal 
Depression Scale (EPDS) 
X    
Perceived Stress Scale 14 (PSS-14) X    
Salivary Cotinine X X X X 
Red Blood Cell Folate X    
Fetal Body Measures    X 
Fetal Ultrasound Brain Measures X X X  
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Table A2.5 Cotinine group-based trajectory model comparisons  
 
2(∆BIC) = log Bayes factor approximation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of   
Latent 
Subgroups 
Number of  
groups in the  
Null Model 
All Linear Terms All Quadratic Terms 
BIC 2(∆BIC) BIC 2(∆BIC) 
2  -1766.9  -1769.6  
3 2 -1745.8 42.2 -1741.6 56.0 
4 3 -1743.6 4.4 -1739.7 3.8 
5 4 -1752.3 -17.4 -1751.23 -23.0 
6 5 -1760.9 -17.2 -1740.5 21.4 
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Table A2.6. Determining the best polynomial degree for each trajectory in a three-group 
model using BIC 
Model Polynomial degree BIC 2*(∆BIC) 
1 1 2 1 -1736.0    
2 1 2 2 -1738.8 -2.8 
3 2 2 1 -1738.8 -2.8 
4 2 2 2 -1741.6 -5.6 
5 1 1 1 -1745.8 -9.8 
6 1 1 2 -1748 -12 
7 2 1 1 -1748.7 -12.7 
8 2 1 2 -1750.9 -14.9 
2(∆BIC) = log Bayes factor approximation. 
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Table A2.7. Cotinine group-based trajectory model comparisons  
 
2(∆BIC) = log Bayes factor approximation. 
 
 
 
 
 
 
 
 
 
 
 
 
Number of   
Latent 
Subgroups 
Number of  
groups in the  
Null Model 
All Linear Terms All Quadratic Terms 
BIC 2(∆BIC) BIC 2(∆BIC) 
2  -1766.9  -1769.6  
3 2 -1745.8 42.2 -1741.6 56.0 
4 3 -1743.6 4.4 -1739.7 3.8 
5 4 -1752.3 -17.4 -1751.23 -23.0 
6 5 -1760.9 -17.2 -1740.5 21.4 
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Table A2.8. Determining the best polynomial degree for each trajectory in a three-group 
model using BIC 
Model Polynomial degree BIC 2*(∆BIC) 
1 1 2 1 -1736.0    
2 1 2 2 -1738.8 -2.8 
3 2 2 1 -1738.8 -2.8 
4 2 2 2 -1741.6 -5.6 
5 1 1 1 -1745.8 -9.8 
6 1 1 2 -1748 -12 
7 2 1 1 -1748.7 -12.7 
8 2 1 2 -1750.9 -14.9 
2(∆BIC) = log Bayes factor approximation. 
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Table A2.9. Model comparisons for estimation method 
Model -2RLL AIC 
Covariance 
Parameter 
Compound Symmetry 8232.1 8238.1 3 
Unstructured 8144.0 8152.0 4 
Autoregressive 8232.1 8232.1 3 
Autoregressive Heterogenous Variances 8144.0 8152.0 4 
Variance Components   
 
8197.9 8214.5 3 
*p<.001. Models with lower -2LL  
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Table A2.10. Basic statistical measures on location and variability of outcomes 
 Mean Median Mode SD Variance 
HC at birth 33.8 34.0 34.0 1.9 3.9 
Brain Weight 10.4 10.4 9.5 1.2 1.5 
BBR 316.1 319.2 319.2 44.4 1972.0 
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Table A2.11. Spearman correlation coefficients for fetal brain outcomes and other continuous 
covariates 
 
Spearman Correlation Coefficients  
Prob > |r| under H0: Rho=0  
Number of Observations 
  Head 
Circumference 
Brain 
Weight 
Brain-
Body 
Ratio 
Gestational 
Age 
Birth 
Weight 
Age 
Head 
Circumference 
 
1.00000 
  
215 
 
1.00000 
<.0001 
215 
 
-0.01923 
0.7792 
215 
 
0.31719 
<.0001 
215 
 
0.69642 
<.0001 
215 
 
0.00734 
0.9148 
215 
 
Brain 
Weight 
  
 
1.00000 
<.0001 
215 
 
1.00000 
  
215 
 
-0.01923 
0.7792 
215 
 
0.31719 
<.0001 
215 
 
0.69642 
<.0001 
215 
 
0.00734 
0.9148 
215 
 
Brain-Body 
Ratio 
  
 
-0.01923 
0.7792 
215 
 
-0.01923 
0.7792 
215 
 
1.00000 
  
215 
 
-0.27356 
<.0001 
215 
 
-0.67971 
<.0001 
215 
 
0.17881 
0.0086 
215 
 
Gestational 
Age 
 
0.31719 
<.0001 
215 
 
0.31719 
<.0001 
215 
 
-0.27356 
<.0001 
215 
 
1.00000 
  
215 
 
0.39817 
<.0001 
215 
 
-0.14460 
0.0345 
215 
 
Birthweight 
 
0.69642 
<.0001 
215 
 
0.69642 
<.0001 
215 
 
-0.67971 
<.0001 
215 
 
0.39817 
<.0001 
215 
 
1.00000 
  
215 
 
-0.11564 
0.0915 
215 
 
Age 
 
0.00734 
0.9148 
215 
 
0.00734 
0.9148 
215 
 
0.17881 
0.0086 
215 
 
-0.14460 
0.0345 
215 
 
-0.11564 
0.0915 
215 
 
1.00000 
  
215 
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Figure A2.1. Histogram and probability plot of birth weight 
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Figure A2.2. Histogram and probability plot of head circumference at birth  
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Figure A2.3. Histogram and probability plot of fetal brain weight 
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Figure A2.4. Histogram and probability plot of fetal body-brain ratios  
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Figure A2.5. Spaghetti plot of the trajectories in head circumference of fetuses of all 
participants on high dose folate in the study 
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Figure A2.6. Spaghetti plot of the trajectories in head circumference of fetuses of all 
participants on standard dose folate in the study 
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September 14, 2010 
 
Hamisu Salihu, M.D., Ph.D. 
Lawton & Rhea Chiles Center  
Lawton and Rhea Chiles Center for Healthy Mothers and Babies 
3111 E. Fletcher Avenue 
Tampa, FL 33612 
 
RE:    Full Board Approval for  
         IRB#: Pro00001437 
         Title:  Preventing fetal body and brain size reduction in low-income smoking mothers: a 
randomized clinical trial 
         Study Approval Period: 8/26/2010 to 8/26/2011 
 
Dear Dr. Salihu: 
 
On 8/26/2010, the Institutional Review Board (IRB) reviewed and APPROVED the above 
application and all documents outlined below. Please note that your approval for this study will 
expire on 8/26/2011.   
 
Approved Items: 
Protocol Document(s): 
 
Berlin Sleep Scale 8/31/2010 12:56 PM 0.01 
Data Capture Sheet (ACOG) 8/31/2010 12:53 PM 0.01 
Dietary Questionnaire 8/31/2010 12:55 PM 0.01 
EPDS 8/31/2010 12:54 PM 0.01 
Epworth Sleepiness Scale 8/31/2010 12:56 PM 0.01 
PI Signed TGH application 7/21/2010 4:55 PM 0.01 
Psychosocial Questionnaire 8/31/2010 12:57 PM 0.01 
Revised Study Protocol 9/10/2010 3:43 PM 0.01 
Revised TGH Application 7/20/2010 3:32 PM 0.01 
Smoking questionnaires 9/10/2010 12:05 PM 0.01 
TGH Signed MOU application 7/21/2010 4:56 PM 0.01 
 
 
Consent/Assent Document(s) 
 
Revised Informed Consent.pdf 9/14/2010 1:35 PM 0.01 
 
 
Please note, if applicable, the informed consent/assent documents are valid during the period 
indicated by the official, IRB-Approval stamp located on the form. Valid consent must be 
documented on a copy of the most recently IRB-approved consent form. As the principal 
investigator of this study, it is your responsibility to conduct this study in accordance with IRB 
policies and procedures and as approved by the IRB. Any changes to the approved research must 
be submitted to the IRB for review and approval by an amendment. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections. If you have any 
questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
Barry Bercu M.D. , Chairperson 
USF Institutional Review Board 
 
Cc: Sarah Croker 
      USF IRB Professional Staff  
 
